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ABSTRACT
Peptide nucleic acid (PNA) is a nucleic acid mimic that shows tremendous 
potential for use in therapeutic and biosensing applications due to its high binding affinity 
for DNA and RNA and its excellent biostability. The therapeutic potential of PNA is 
hindered, however, by poor cellular uptake, solubility, and bioavailability. Although 
various approaches have been taken to overcome these critical limitations and realize 
the full potential of PNA, more efficient solutions are still desired. We hypothesize that 
negatively charged PNA analogues would electrostatically mimic DNA and RNA, thus 
overcoming the limitations mentioned above. This dissertation is mainly focused on our 
initial studies to investigate the tolerance of the PNA structure to the addition of 
negatively charged side chains.
We explored the effect of ionic strength on binding affinity for modified PNAs 
having either negatively charged side chains or positively charged side chains (Chapter 
2). We observed that as ionic strength is increased, negatively charged PNA increases 
in affinity for DNA and RNA, whereas positively charged PNA decreases in affinity for 
DNA and RNA. The point at which these trends intersect hovers near physiological salt 
concentration. In a simulated physiological buffer, negatively charged PNA shows 
slightly higher affinity for RNA whereas positively charged PNA shows slightly higher 
affinity for DNA. Intrigued by the effect of side chain structure and electrostatics on 
binding affinity, we were also curious to explore the mismatch and orientation selectivity 
of these y-substituted PNAs (Chapter 3). We observed that positively charged side 
chains provide higher selectivity in DNA binding, while negatively charged side chains
provide higher selectivity in RNA binding.
Our results provide insight into the impact of side chain structure and 
electrostatics on the binding affinity and selectivity with DNA and RNA under 
physiological conditions. Since PNA can be negatively charged without sacrificing 
binding affinity and selectivity, we anticipate that these molecules will show promise as 
therapeutics that take advantage of both the inherent benefits of PNA and the multitude 
of charge-based delivery technologies currently being developed for DNA and RNA.
PNA also shows promise for use in synthetic biology applications, but the 
evolution of abiotic polymers such as PNA requires methods for sequence encoding and 
amplification. Chapter 4 describes our efforts to synthesize a modified PNA monomer 
that is designed to polymerize using dynamic reaction conditions.
DNA-based micelles have the potential to be used as stimuli-responsive 
materials due to their ability to undergo programmable assembly and disassembly. 
Chapter 5 outlines our synthesis of a potential multivalent micellar scaffold.
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PEPTIDE NUCLEIC ACID: A VERSATILE NUCLEIC ACID ANALOGUE
“Molecular recognition between nucleic acids via nucleobase complementarity is 
probably the most elegant molecular recognition system in nature. It is beautifully simple, 
yet very powerful.”
- Peter E. Nielsen1
Nucleic acids, together with this powerful molecular recognition system, provide 
high fidelity information transfer via the processes of replication, transcription, and 
translation, and this system is the key to our existence. Naturally occurring nucleic acids, 
2’-deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), are polymers of nucleotides, 
and contain a phosphate group, a sugar moiety, and a nucleobase. The molecular 
recognition between nucleic acids predominantly occurs via “Watson-Crick base-pairs” 
(Figure 1.1, 1.2), which consist of noncovalent hydrogen bonds between two 
complementary purine-pyrimidine base-pairs (adenine-thymine/uracil and guanine- 
cytosine).2 In addition, non-Watson-Crick base pairing modes such as Hoogsteen3 and 
wobble4 are also possible (Figure 1.3). In Hoogsteen mode, thymine pairs with an 
adenine, which is already involved in Watson-Crick A:T base pair, and protonated 
cytosine pairs with guanine of a Watson-Crick C:G base pair, and thus enable formation 
of triplexes. In wobble base pairing, purine bases recognize noncomplementary 
pyrimidine bases.
The potential of nucleic acids is not just limited to bioevolution, but they also play 
a diverse role in numerous disciplines, including therapeutics, diagnostics, research, and
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Figure 1.1. Watson-Crick complementary nucleobase pairs.
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Figure 1.2. Schematic representation of DNA:RNA duplex.
nanotechnology. In particular, nucleic acids have shown great promise for the treatment 
of various conditions, including cancer, diabetes, cystic fibrosis, and other genetic 
disorders.5 One therapeutic approach to treat these diseases is known as the ‘antisense 
strategy’, in which gene expression is silenced by binding complementary 
oligonucleotides (AON) to the disease-causing mRNA sequence. This prevents the 
translation of proteins either by sterically blocking translation or recruiting RNase H 
enzyme to degrade the RNA strand in the mRNA-AON duplex (Figure 1.4).6 In the 
‘antigene strategy’, transcription or replication processes are interrupted by binding of 
the AON to DNA.7
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Figure 1.3. Non-Watson-Crick base pairing modes a) Hoogsteen base pairing for A:T 
and G:C base pairs and (b) representative wobble base pairs.
Figure 1.4. Antisense and antigene pathways [reprinted with permission from (Jain, M. 
L.; Bruice, P. Y.; Szabo, I. E.; Bruice, T. C. Chem. Rev. 2011, 112, 1284-1309).8 
Copyright (2012) American Chemical Society].
4Nucleic Acid Analogues
The use of native nucleic acids for therapeutic applications comes with specific 
obstacles, including degradation by endogenous enzymes, poor pharmacokinetics, and 
low intrinsic binding affinity.9 However, modified nucleic acid analogues have the 
potential to overcome these challenges. Nucleic acids can be modified at the backbone, 
sugar, or nucleobase; and these nucleic acid analogues have gained widespread use in 
therapeutic and diagnostic applications (Figure 1.5).10
Synthetic oligonucleotides having modified backbones have been extensively 
studied in antisense and numerous other biological applications (Figure 1.6). 
Phosphorothioate (PS) oligonucleotides are one example of ‘first generation’ antisense 
oligonucleotides; these are synthesized by replacing one of the nonbridging phosphate 
oxygen atoms with a sulfur atom, thus improving enzymatic stability and 
pharmacokinetics. The first PS-based antisense drug, Vitravene™ (ISIS-2922), was 
approved by the FDA in 1998 to treat cytomegalovirus retinitis in immunocompromised 
patients.11 Although PS has remained the most successful and widely used 
oligonucleotide analogue until now, it does have disadvantages, such as lowered duplex 
stability, existence of diastereomeric mixtures, and toxicity induced by nonspecific 
protein binding.12 Similarly, phosphoramidates are synthesized by replacing the 3’- 
hydroxyl of the backbone with an amine.13 Phosphoramidates show increased duplex 
stability and nuclease resistance but they do not induce RNase H-dependent 
degradation of the complementary RNA strand in a duplex.9 Phosphoramidates have 
been further modified by replacing one of the nonbridging phosphate oxygen atoms with 
a sulfur atom, providing acid-stable thiophosphoramidates, which have exhibited 
anticancer activity.14,15
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Figure 1.5. Potential sites of modification of nucleic acids [adapted from (Sharma, V. K.; 
Rungta, P.; Prasad, A. K. RSC Adv. 2014, 4, 16618-16631) with permission of The 
Royal Society of Chemistry].
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Figure 1.6. Chemical structures of a selection of nucleic acid analogues having 
modifications in the (a) phosphate backbone or (b) 2 -position of ribose sugar moiety.
6Modification of the 2'-position of the ribose sugar moiety to give analogues such 
as 2 '-fluoro and 2 '-0-alkyl nucleotides has also gained success in therapeutic 
applications (Figure 1.6). Among these ‘second generation’ antisense oligonucleotides, 
2'-0-methoxyethyl (MOE) was the most successful candidate in terms of affinity, 
stability, and entering into clinical trials.9 In 2013, the FDA approved the second 
antisense drug, Mipomersen (Kynamro), to treat homozygous familial 
hypercholesterolemia in patients with high levels of low-density lipoprotein cholesterol.16 
This drug also contains a PS oligonucleotide sequence, where each end of the 
sequence contains five nucleotides with 2-MOE modifications.
In addition to 2'-substitution of ribose, the ribose sugar moiety itself can be 
replaced by various nonnatural sugar or cyclic structures to obtain nucleic acid 
analogues (Figure 1.7). Among these ‘third generation’ antisense oligonucleotides are 
arabinose nucleic acid (ANA) consisting of an inverted 2'-configuration compared to 
native RNA,17 hexitol nucleic acid (HNA) containing a pyranose moiety, and cyclohexene 
nucleic acid (CeNA) containing a cyclohexene ring instead of the furanose sugar moiety 
of native nucleic acids.12,18 ANA exhibits higher affinity to RNA than DNA, but overall 
lower affinity relative to PS oligonucleotides.12 Similarly, HNA shows increased nuclease 
resistance and higher affinity to RNA than DNA. Both ANA and CeNA can induce RNase 
H-dependent degradation of the complementary RNA strand in antisense therapy.
In an attempt to reduce the entropic cost of duplex formation, and thus increase 
binding affinity, structurally constrained, bicyclic nucleic acid analogues, such as locked 
nucleic acid (LNA) were developed (Figure 1.7).19,20 LNA and LNA analogues have 
shown great promise in numerous biomedical and nanotechnology applications, 
including antisense therapy, due to their higher binding affinity, selectivity, and stability.21 
In contrast to locking the backbone, the C2'-C3' bond of ribose can be cleaved to give a
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Figure 1.7. Chemical structures of a selection of nucleic acid analogues (continued).
8flexible nucleic acid analogue, unlocked nucleic acid (UNA). Although UNA reduces 
duplex stability, conjugates of UNA with other antisense oligonucleotides have been 
investigated to achieve flexibility in binding and enhance stability.22 Another simply- 
structured nucleic acid analogue, glycol nucleic acid (GNA), has shown promise for 
biotechnology applications due to its higher duplex stability with DNA and RNA, in 
contrast to UNA (Figure 1.7).23
All of the aforementioned nucleic acid analogues retain either the phosphate 
group or ribose sugar moiety. In contrast, replacement of the sugar-phosphate backbone 
with an isostere gives rise to morpholino phosphorodiamidate (MO) and peptide nucleic 
acid (PNA), which are both neutrally charged due to the lack of a phosphate group 
(Figure 1.7).9 Both PNA and MO are promising antisense agents and are stable to 
nucleases, but PNA shows much higher affinity to DNA and RNA than MO.24,25
Peptide Nucleic Acid (PNA)
PNA was first reported by Peter E. Nielsen, Michael Egholm, Rolf H. Berg, and 
Ole Buchardt in 1991,26 and was originally designed as a triplex-forming oligonucleotide 
mimic to bind double-stranded DNA in the major groove via Hoogsteen base pairing.26,27 
However, it was later realized that PNA can also bind to single-stranded nucleic acids.28 
The unique physicochemical properties of PNA can largely be attributed to its achiral, 
neutral, peptide-like W-(2-aminoethyl)glycine backbone in place of the sugar-phosphate 
backbone found in DNA and RNA (Figure 1.8). The nucleobases are linked to secondary 
amines in the PNA backbone via methylene carbonyl linkages.26 PNA is neither a protein 
nor a nucleic acid and has thus become a promising biomolecular tool with an enhanced 
lifetime for in vivo and in vitro applications, such as molecular diagnostics and antisense 
therapeutics, as it can withstand both nucleases and proteases.24,29'31
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Figure 1.8. Chemical structures of peptides and base pairing between PNA and 
DNA/RNA. The characteristic amide (peptide) bond of both PNA and peptide is 
highlighted. PNA is depicted as a peptide having N-terminus and C-terminus. Alignment 
of the N-terminus of PNA with the 3’-end of DNA/RNA is known as the antiparallel 
orientation. [Adapted with permission from (Nielsen, P. E. Acc. Chem. Res. 1999, 32, 
624-630). Copyright (1999) American Chemical Society.]
In addition to high affinity, PNA shows high selectivity in binding to DNA and 
RNA. PNA is more vulnerable to base mismatches than are native nucleic acids, due to 
the constrained flexibility of the PNA backbone and the inherent asymmetry in 
PNA:DNA/RNA duplexes.32 PNA can bind to complementary nucleic acids in both 
parallel and antiparallel orientations because of its achiral backbone, but generally 
prefers the antiparallel orientation in binding with nucleic acids (Figure 1.8). The potential 
of PNA to hybridize with complementary DNA/RNA with high affinity and selectivity 
following Watson-Crick rules,28 and also the ability to invade double stranded-DNA,33,34 
has even led to the speculation that PNA may have been a prebiotic material.35 This 
interest in finding the relationship of PNA to the origin of life has inspired the recent 
discovery of PNA-like materials in cyanobacteria.36
10
Structures of PNA in complex w ith PNA and nucleic acids
Structural information has been obtained for duplexes of PNA:DNA37 and 
PNA:RNA38 using NMR, while structures of PNA2:DNA triplex39 and PNA:PNA40 
duplexes were solved by using X-ray crystallography (Figure 1.9). According to these 
data, PNA:RNA duplexes adopt the A-form structure preferred by RNA,38 whereas 
PNA:DNA duplexes adopt an intermediate structure between A- and B-form, in which the 
base stacking is more A-like.37,41,42 PNA:PNA duplexes40 and (PNA)2-DNA triplexes39 
adopt a P-form structure preferred by PNA, which is different from both A- and B-form 
but more like A-form. Consequently, PNA:RNA duplexes generally show a higher 
thermal stability relative to analogous PNA:DNA duplexes. These data provide evidence 
that the backbone geometry and constrained flexible structure of PNA could be the 
major factors that facilitate stronger affinity with nucleic acids, as PNAs can easily adopt 
the desired geometries of DNA or RNA by enthalpy-entropy compensation.1
PNA-RNA PNA-DNA PNA-DNA-PNA PNA-PNA
Figure 1.9. Structures of PNA complexes: side view (top) and upper view (bottom). 
[Reprinted with permission from (Nielsen, P. E. Acc. Chem. Res. 1999, 32, 624-630; 
Copyright (1999) American Chemical Society) and (Eriksson, M.; Nielsen, P. E. Q. Rev. 
Biophys. 1996, 29, 369-394; Copyright (1996) Cambridge University Press)].
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PNA backbone modifications
The ease of altering the PNA backbone has encouraged synthetic organic 
chemists to develop various PNA analogues to enhance properties such as binding 
affinity with nucleic acids and cellular delivery (Figure 1.10).30 Consequently, PNA has 
been modified by the introduction of conformationally constrained cyclic backbones, 
different substituents, or modified nucleobases.1 For example, when the amide group in 
the backbone is replaced with an amine to remove the rigidity imposed by the amide, 
this results in reduced binding affinity. This illustrates the significance of the “constrained 
flexibility” of the PNA backbone. To enhance the rigidity, a cyclic group such as 
cyclohexyl has been incorporated in the ethylene diamine portion of the PNA backbone, 
but results in a decrease in binding affinity.43 However, the introduction of cyclopentyl44 
and proline45 groups into the backbone has improved binding affinity. Moreover, in an 
effort to enhance the solubility and cellular delivery of PNA, charged PNA has been 
developed by incorporating functional groups such as phosphates in PNA backbone.30
Raco Base
n  H
Ethylamine PNA Cyclohexyl PNA Aminoproline PNAaeg-PNA
Base Base Base Base
R
Phosphono PNA a-substituted PNA p-substituted PNA y-substituted PNA
Figure 1.10. Chemical structures of a selection of modified PNAs.
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Among PNA modifications, the use of various amino acids for the synthesis of 
PNA provides a facile way to incorporate diverse substituents with different chirality at 
the a, p, or y-positions of PNA. Installation of L-amino acids at the a-position and D- 
amino acids at the y-position is detrimental to PNA binding, but L-amino acids at the y- 
position and D-amino acids at the a-position enhance binding affinity. Further, 
substitution at the y-position is known to be advantageous over substitution at the a- 
position, with regard to binding affinity, unambiguous antiparallel binding, and helical 
induction.41,46-51 p-substituents have only been investigated recently, but exhibited 
reduced affinity.52 Specifically, a (S)-stereocenter at the y-position (from L-amino acids) 
conformationally preorganizes the PNA backbone into a right-handed helix, which is 
favorable for binding to DNA and RNA.51 This stereoinduction is unidirectional from the 
C- to N-terminus, resulting in an antiparallel sequence alignment, and projects the y- 
substituents away from the backbone. This ease of modifying the PNA backbone with 
amino acids allows incorporation of different functional groups to enhance properties 
such as stronger binding, intercalation, enhanced solubility, and cellular delivery.47,53
PNA nucleobase modifications
In addition to backbone modifications, PNA has also been synthesized using 
“non-Watson-Crick” nucleobases to achieve higher duplex/triplex stabilities (Figure
1.11).30 For instance, replacement of adenine by diaminopurine increases the melting 
temperature (Tm) of PNA with nucleic acids by ~4 oC per substitution. In addition, PNA 
modified with diaminopurine and thiouracil can invade double-stranded DNA in antigene 
applications. Similarly, cytosine has been replaced with pseudoisocytosine, which can 
bind with guanine irrespective of the surrounding pH via Hoogsteen base pairing in 






N-benzoyl-cytosine G-clamp P-base E-base
Figure 1.11. Chemical structures of a selection of modified nucleobases.
base has increased duplex stability via both base pairing and base stacking, while 
enhancing the solubility due to positively charged side chains.54 Recently, Rozners and 
coworkers have reported that PNA monomers modified with P and E nucleobases were 
able to isolate pyrimidine interruptions in polypurine tracts of double helical RNA.55,56
PNA has been utilized in a diverse range of applications, including therapeutics, 
diagnostics, molecular biology, and nanotechnology, due to its unique physicochemical 
properties. For example, PNA is effective in antisense and antigene applications, where 
stronger binding of PNA to mRNA and DNA inhibits the processes of translation, 
transcription, and replication.57 Since RNase H does not recognize the PNA: RNA duplex 
as a substrate, antisense activity occurs via sterically blocking mRNA translation rather 
than degradation of RNA strand.24 Similarly, PNA displays antigene properties by
Applications of PNA
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binding to single-stranded DNA (during replication)58 and double-stranded DNA (Figure
1 .12).1
The antisense and antigene potential of PNA has been explored to develop 
anticancer and antimicrobial PNAs. For example, PNA has shown anticancer effects by 
suppressing telomerase activity,59 c-myc oncogene,60 and T antigen61 expression. PNA 
has exhibited antimicrobial properties by silencing gene expression in bacteria, viruses, 
and amoebae.62 For instance, PNA has inhibited bacterial translation in vitro with an 
efficiency comparable to tetracycline.24,63 However, the in vivo performance was severely 
hindered by poor cellular uptake of PNA.24
The detection of single nucleotide polymorphisms (SNPs) facilitates the 
diagnosis of genetic diseases, as these slight changes in DNA sequences lead to drastic 
changes in gene expression or protein function. The highly sequence-specific binding of 
PNA has been utilized to develop biosensors for SNP detection. For instance, 
immobilization of PNA into a synthetic ion channel has facilitated the discrimination 
between complementary DNA and mismatched sequences.64 Moreover, efficient and 
sensitive PNA fluorescence in situ hybridization (FISH) techniques have been developed 
for quantitative telomere analyses, chromosome painting, and genotyping of viruses and 
bacteria (Figure 1.13).24
Cellular delivery of PNA
Oligonucleotides are not cell permeable by simple diffusion due to the 
hydrophobic nature of the membrane lipid bilayer. For instance, negatively charged 
siRNAs or antisense moieties, as well as charge neutral methylphosphonates, PNAs,65 
or MOs are not cell permeable. Despite the uncharged nature of PNA, its large size 
(>2000 Da) prevents eukaryotic and prokaryotic cell permeability.24,25 However, in some 
cell lines, antisense effects have been observed when PNA was used in fairly high
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Figure 1.12. PNA binding modes to target double stranded DNA (A) triplex, (B) triplex 
invasion, (C) duplex invasion, and (D) double duplex invasion (thick structures indicate 
PNA). [Reprinted with permission from (Nielsen, P. E. Acc. Chem. Res. 1999, 32, 624­
630). Copyright (1999) American Chemical Society].
P. aeruginosa
Figure 1.13. PNA-fluorescence in situ hybridization (FISH) technique (reproduced with 
permission from reference 66).
concentrations (10-100 ^M).30 Several methods have been introduced to overcome this 
critical delivery issue of PNA, ranging from physical or electrical disruption of the cell 
membrane to chemical complexation, conjugation, or modification of PNA.24 Temporary 
disruption of cell membranes by electroporation, pore-forming agents, and physical 
scrape loading have been successful in some systems; for instance, a 20mer PNA 
microinjected into cells has reduced T antigen expression.61 However, due to the stress 
applied by these methods, they are mainly limited to cultured cells.24
Great efforts have been taken to modify PNA to enable effective cellular
16
penetration. As an example, conjugating fatty acid chains or adamantyl moieties 
increases the lipophilicity of PNA, enabling its cellular uptake.24 Additionally, conjugation 
of PNA to cell penetrating peptides (CPPs), including Tat and penetratin, is a popular 
method of PNA cellular delivery.56 PNA is rapidly excreted by the kidneys, thus limiting 
its bioavailability, but chemical conjugation to cationic peptides may increase its 
circulation time.30 However, the bioavailability of PNA delivered via CPP is controlled by 
endosomal release. As a consequence, endosomal disruption methods, such as 
photochemical internalization, Ca2+ treatment, or chloroquine treatment, have been 
reported to enhance the efficacy of PNA delivered via CPP.67 Unfortunately, CPPs are 
relatively large peptides, making synthesis complicated and also leading to nonspecific 
toxic effects.56
Interest was instead drawn towards using short sequences of cationic peptides 
such as oligolysine and oligoarginine. For example, PNA covalently linked to a peptide 
(PKKKRKV) has down-regulated c-myc oncogene expression.60 Covalently linking PNA 
to cationic shell-cross-linked knedel-like nanoparticles, lipophilic triphenylphosphonium 
cations, and polyethylenimine have also enhanced cellular delivery.56
The use of amino acids to introduce positively charged side chains at the a- or y- 
position of PNA is more promising than conjugation to cationic peptides or CPP in terms 
of low cytotoxicity and convenience in synthesis. Accordingly, Ly and colleagues 
introduced GPNA (guanidine-based PNA),68 inspired by the remarkable cellular uptake 
properties and activity of the human HIV-1 Tat transduction domain (YGRKKRRQRRR)69 
and the homoarginine peptoid70 (Figure 1.14). Similarly, Ganesh and coworkers reported 
cationic PNA having aminomethylene side chains.50,71 Of the cationic modifications 
investigated by the Ly and Ganesh research groups, y-GPNA48 and y-aminomethylene 
PNA50,71 have demonstrated the most promising results in terms of binding, cellular 
uptake, and antisense activity. PNAs having positively charged side chains, however,
17
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Figure 1.14. Chemical structures of y-PNA having cationic side chains.
can lead to nonspecific binding due to electrostatic interactions with negatively charged 
nucleic acids.72
Negatively charged PNA: an attempt to enhance cellular delivery
The development of methods to enhance the circulation lifetime and cell 
permeability of nucleic acids in vivo is an ongoing area of research. In particular, the 
success and widespread application of RNA interference (RNAi) and numerous gene 
manipulation applications rely on the discovery of clinically suitable, safe, and effective 
delivery methods.73,74 Anionic oligonucleotides are efficiently delivered into cells by cell- 
targeting ligands and nanocarriers, including cationic polymer complexes and polymeric 
nanoparticles.74 However, nearly all of these technologies function on the basis of the 
negatively charged backbone found in native nucleic acids.
Although the inherent neutral charge of PNA limits the use of these methods, 
complexation with partially complementary oligonucleotide has facilitated the delivery of 
PNA into cells via cationic liposomes.24 But some optimization of the carrier 
oligonucleotide is required to ensure that PNA is released once inside cells. 
Furthermore, PNA-DNA chimeras were introduced to take advantage of the 
aforementioned delivery methods and to increase solubility (Figure 1.15).75 Although
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Figure 1.15. Negatively charged PNA analogues.
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PNA-DNA chimeras have been taken up by cells and demonstrated antisense 
properties, synthesis of these chimeras is challenging due to the requirement for 
orthogonal protecting groups to ensure stability of DNA.76
The abovementioned limitations can be overcome when PNAs having negatively 
charged groups are synthesized. Nielsen and coworkers investigated phosphonate- 
peptide nucleic acid conjugates containing twelve phosphonate moieties per PNA 
oligomer, which were derived from phosphonate modified glutamine or lysine (Figure 
1.15). These negatively charged PNAs have been delivered to HeLa cells by cationic 
lipids and exhibited dose-dependent antisense activity in the nanomolar range.77
Taking a different approach to charge incorporation, the research groups of 
Peyman and Efimov independently synthesized and studied phosphono PNA 
(pPNA/PHONA), having a negatively charged phosphate group inserted into the PNA 
backbone (Figure 1.15).78"80 Efimov and colleagues have also investigated 
conformationally constrained chiral phosphono-PNA analogues based on 
4-hydroxyproline (pHypNAs). Although negatively charged, these analogues have been 
delivered into cells mostly via microinjection;81"83 and selective regulation of 
developmentally important genes was achieved using caged PNA,81 HypNA-pPNA,82 
and phosphonic ester PNA83 in fish embryos. However, these modifications often 
affected the binding affinity of PNA with DNA and RNA. Moreover, synthesis of these 
negatively charged PNA analogues is more challenging than the incorporation of 
negatively charged side chains into PNA using amino acids.
Accordingly, incorporation of negatively charged side chains from amino acids 
(D-Glu, L-Asp) at the a-position of PNA has been investigated, but resulted in reduced 
binding affinity with DNA.68,84,85 As the introduction of side chains at the y-position of PNA 
enhances its binding properties, we hypothesized that negatively charged y-side chains 
would overcome the aforementioned limitations, thus facilitating the use of delivery
20
vehicles currently being developed for DNA and RNA. This hypothesis is further 
supported by recent work providing the evidence that negatively charged side chains (L- 
Glu, sulfate) are tolerated at the y-position (Figure 1.15).46,86
Objectives of this Dissertation
Ever since the DNA double helix structure was elucidated by Watson and Crick in 
1953,2 tremendous strides have been made toward understanding the structure and 
function of nucleic acids, as well as the use of nucleic acid analogues in biomedical 
applications. These efforts led to the invention of PNA, a nucleic acid mimic with 
remarkable binding properties and potential to be used in numerous therapeutic, 
diagnostic, and nanotechnology applications. The therapeutic potential of PNA, however, 
is hindered by its poor solubility, cellular uptake, and bioavailability, predominantly due to 
its uncharged backbone. Although various approaches have been taken to overcome 
these critical limitations and realize the full potential of PNA, more efficient and attractive 
solutions are still desired.
We hypothesized that negatively charged PNA analogues would electrostatically 
mimic DNA and RNA and thus be compatible with conventional nucleic acid delivery 
technologies. This dissertation will primarily focus on our studies to investigate the 
effects of negatively charged side chains on PNA. We investigated the duplex stability of 
charge-modified PNA with DNA and RNA (in Chapter 2), and the sequence recognition 
ability and duplex structures of modified PNA (in Chapter 3). Our results provide insight 
into the binding affinity and selectivity of modified PNA in antisense and antigene 
applications.
PNA also shows promise for use in synthetic biology applications, but the 
evolution of abiotic polymers such as PNA requires methods for sequence encoding and 
amplification. Nonenzymatic, templated polymerization allows the generation of
21
sequence-defined, genetically-encoded synthetic polymers with desired functional 
properties. Although significant work has been done related to DNA-templated PNA 
polymerization, a system that can execute polymerization from single-monomer building 
blocks with high fidelity is still needed. Chapter 4 of this dissertation will emphasize the 
Heemstra group’s efforts toward developing a modified PNA monomer that could 
overcome the aforementioned limitation by taking advantage of dynamic covalent 
chemistry.
The Heemstra group is also involved in investigating DNA-based micelles, as 
they have the potential to be used as stimuli-responsive materials due to their ability to 
undergo programmable assembly and disassembly. Chapter 5 of this dissertation will 
highlight the design and synthesis of a potential micellar scaffold, which can undergo 
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CHAPTER 2
TAILORING PEPTIDE NUCLEIC ACIDS TO ELECTROSTATICALLY 
MIMIC DNA AND RNA1 
Introduction
Peptide nucleic acid (PNA) is a nucleic acid mimic that shows tremendous poten­
tial for use in therapeutic and biosensing applications due to its high binding affinity and 
selectivity for DNA and RNA and its excellent biostability.1,2 The therapeutic potential of 
PNA, however, is hindered by its poor solubility, cellular uptake, and bioavailability, pre­
dominantly due to its uncharged backbone. The Heemstra group hypothesizes that neg­
atively charged PNA analogues would electrostatically mimic DNA and RNA, overcoming 
the abovementioned challenges by taking advantage of the multitude of charge-based 
delivery technologies currently being developed for DNA and RNA. However, the en­
hanced thermodynamic stability of PNA:DNA and PNA:RNA duplexes compared with 
DNA:DNA and DNA:RNA duplexes has been in part attributed to the lack of electrostatic 
repulsion between the uncharged PNA backbone and negatively charged DNA or RNA 
backbone.3 This previous hypothesis has led to the belief that having a negative charge 
on PNA is detrimental to the duplex formation of PNA with native nucleic acids, and thus 
discouraged the development of negatively charged PNA analogues.
This hypothesis is further supported by the reduced binding affinities observed in
1 Adapted under the terms of the Creative Commons Attribution License from De Costa, N. T. S.;
Heemstra, J. M. Evaluating the Effect of Ionic Strength on Duplex Stability for PNA Having
Negatively or Positively Charged Side Chains. PLoS ONE 2013, 8, e58670.
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some of the previously reported negatively charged PNA analogues.4-6 For example, 
negatively charged pPNA:DNA and pPNA:RNA duplexes were found to have Tm values 
significantly lower than those of PNA:DNA and PNA:RNA, and, in fact, even lower than 
those of the corresponding DNA:DNA and DNA:RNA duplexes. But alternating pPNA 
monomers with PNA monomers to give a pPNA-PNA hybrid resulted in duplex stabilities 
with DNA and RNA that approached those of PNA:DNA and PNA:RNA.6 In addition, oli­
gomers of alternating pPNA-HypNA monomers showed higher duplex stabilities with 
DNA and RNA than oligomers of pPNA-PNA, yet lower than PNA:DNA and PNA:RNA.6 
The results of these studies could be interpreted to conclude that increasing negative 
charge decreases PNA duplex stability via electrostatic repulsion. However, it is im­
portant to note that the backbone conformation of pPNA is likely to differ significantly 
from that of PNA and a- or y-substituted PNA. Thus the decreased duplex stability of 
pPNA may result predominantly from structural rather than electrostatic effects.
Previous studies have also attempted to introduce charged side chains at the a- 
and y-positions of the PNA backbone. For example, incorporation of negatively charged 
(D-Glu, L-Asp) or neutral (L-Leu, L-Ile) side chains at the a-position reduces binding af­
finity with DNA, whereas the incorporation of positively charged (D-Lys) side chains in­
creases binding affinity with DNA and has negligible effects on binding affinity with 
RNA.7-9 However, these studies were only carried out at a single salt concentration, and 
the binding affinity of negatively charged PNA with RNA was not studied. In the case of 
y-substituted PNA, positively charged (L-Lys, L-Arg), or neutral side chains (L-Phe, L- 
Val) increase the binding affinity with DNA,10-15 though this increase is primarily attributed 
to steric or hydrogen-bonding effects leading to conformational preorganization of the 
PNA backbone.16,17 There is evidence that negatively charged side chains (L-Glu, sul 
fate) are also tolerated at the y-position,11,18 but their effect on binding affinity with DNA at 
varying ionic strength has not been thoroughly studied. Additionally, the binding proper­
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ties of y-substituted PNA with RNA have only been minimally investigated.10
Although electrostatic repulsion can obstruct duplex formation between negative­
ly charged nucleic acids and negatively charged PNA, we anticipate that Debye screen­
ing of this electrostatic repulsion by the counter ions in the medium could overcome this 
repulsion.19,20 However, there are no reported studies that systematically evaluate the 
effect of ionic strength on duplex stability for PNAs having a charged backbone. Our at­
tempts to study negatively charged PNA analogues focused on installing Asp residues at 
the y-position of PNA. While our manuscript was under review,21 Romanelli and cowork­
ers reported a negatively charged PNA analogue containing Y-sulfate side chains.18 They 
observed that doubling the salt concentration increased the stability of PNA2:DNA tri­
plexes containing Y-sulfate PNA; yet, they did not thoroughly evaluate the effect of ionic 
strength on duplex stability of negatively charged Y-sulfate PNA.
In this chapter, we present the first detailed investigation of the effect of ionic 
strength on binding affinity for charged PNA. We show that charge screening of electro­
static repulsion by counterions in solution enables negatively charged side chains to be 
incorporated into the PNA backbone without reducing duplex stability with DNA and 
RNA.21 While electrostatic interactions do play a role in PNA binding, this effect is mani­
fested in differential salt dependence, such that at medium to high salt concentrations, 
negatively charged PNA actually binds more strongly to DNA and RNA than does posi­
tively charged PNA.
Results and Discussion 
Monomer synthesis
The desired Y-substituted PNA monomers were synthesized from commercially 
available Fmoc-L-aspartic acid p-te/f-butyl ester 2.1a, Fmoc-L-Lys(Boc)-OH 2.1b, and 
Fmoc-L-Ala-OH 2.1c using previously reported procedures (Scheme 2.1).11 First, Fmoc-
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Scheme 2.1. Synthesis of y-substituted PNA monomers.
protected amino acid 2.1 was reduced to give the corresponding alcohol 2.222 in quanti­
tative yield, which was subsequently subjected to Parikh-Doering conditions23 to yield 
aldehyde 2.3.24 Aldehyde 2.3 was immediately subjected to reductive amination with gly­
cine benzyl ester 4-toluenesulfonate to afford the y-substituted PNA backbone 2.4. Sub­
sequent coupling of 2.4 with thymine-1-acetic acid using HATU/DIPEA yielded amide 
2.5. Final removal of the benzyl ester via hydrogenation produced y-substituted PNA 
monomer 2.6.
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Structure and sequence of modified PNA strands
To investigate the effect of ionic strength on duplex stability for charged PNA, 
negatively25 and positively11 charged PNA monomers and y-methyl substituted PNA 
monomer26 were synthesized using L-Asp, L-Lys and L-Ala residues, respectively to 
construct the ethylenediamine portion of the PNA backbone (Figure 2.1). We used the 
Nielsen decamer sequence H-GTAGATCACT-NH2 3 for the current study, as its hybridi­
zation to DNA and RNA has been thoroughly investigated. This sequence contains three 
equally-spaced thymine residues as convenient points for substitution with our charged 
monomers. We used solid-phase peptide synthesis27 (SPPS) to generate our nonfunc- 
tionalized PNA (PNA nf), as well as PNA strands containing either one or three positive­
ly charged (PNA 1pos/3pos), negatively charged (PNA 1neg/3neg), or y-methyl substi­
tuted (PNA 1Me/3Me) PNA monomers (Table 2.1). With these sequences in hand, we 
investigated their thermal melting behavior with complementary DNA (DNA 1) and RNA 
(RNA 1) at varying salt concentrations.
The effect of ionic strength on duplex stability fo r DNA, RNA, and PNA
DNA:DNA and DNA:RNA duplexes are known to demonstrate positive salt de­
pendence, in which increased ionic strength of the buffer solution leads to increased 
melting temperature (Tm) due to charge screening of the electrostatic repulsion between 
the negatively charged strands.19 Thus, we were not surprised to see the Tm values of 
DNA 1:DNA 2 and RNA 1:DNA 2 increase with increasing concentrations of NaCl (Fig­
ure 2 .2).
In contrast, PNA:DNA duplexes demonstrate negative salt dependence, in which 
increased ionic strength leads to a decrease in Tm.3 The thermodynamic stability of 
PNA:DNA duplexes has been attributed in part to entropically favorable counterion re­
lease upon duplex formation.28 Therefore, increasing the salt concentration destabilizes
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T : R = H 
Td: R = CH2C02- 
Tk:R = (CH2)4NH3+ 
Ta:R = CH3
H
Figure 2.1. Chemical structure of y-substituted PNA monomers.
Table 2.1. PNA,* DNA, and RNA sequences.
Name Sequence
PNA nf h -g ta g a tc a c t - n h 2
PNA 1neg H-GTAGATdCACT-NH2
PNA 3neg h - g tda g a tdc a c t d-n h 2
PNA 1pos H-GTAGATkCACT-NH2






* PNAs are depicted like peptides by convention with the N-terminus 
at the left position and the C-terminus at the right.
25 -|------------------- 1--------------------1--------------------1------------------- r
0 250 500 750 1000
[NaCI] (mM)
Figure 2.2. Tm vs [NaCl] for DNA 1:DNA 2 and RNA 1:DNA 2 duplexes. 
(Conditions: 3 ^M DNA, 3 ^M RNA, 10 mM sodium phosphate buffer with added 
NaCl, pH 7.2. Error bars represent standard deviation of three independent trials.)
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the PNA:DNA duplex. However, the efflux of cations in PNA:DNA duplex formation is 
less than the influx of cations in DNA:DNA duplex formation, so the net salt effect is 
smaller for PNA:DNA relative to DNA:DNA. As anticipated, the Tm of PNA nf:DNA 1 
shows a weak negative salt dependence (Figure 2.3, green line). In the case of 
PNA:RNA duplexes, ionic strength appears to have little effect on hybridization, as PNA 
nf:RNA 1 shows neutral salt dependence (Figure 2.4, green line). In previous work by Ly 
and colleagues, positively charged guanidinium-PNA (GPNA):DNA duplexes demon­
strated negative salt dependence.12 Conversely, Romanelli and coworkers have shown 
that in the case of PNA2:DNA triplexes containing negatively charged PNA, doubling salt 
concentration increases stability.18 Thus, we anticipated that our negatively charged PNA 
would demonstrate positive salt dependence in duplex formation with DNA and RNA.
Duplex stability of charged PNA with DNA at varying salt concentrations
The introduction of a single positive or negative-substituent was found to en­
hance PNA:DNA duplex stability, as PNA 1pos:DNA 1 and PNA 1neg:DNA 1 displayed 
higher Tm values than PNA nf:DNA 1 (Figure 2.3a). This increase in duplex stability can 
be attributed primarily to backbone preorganization induced by the y-substituent, as an 
analogous PNA strand having a single y-methyl substituent (PNA 1Me) 29-31 demonstrat­
ed nearly identical Tm values to PNA 1pos (Table 2.2). Similar to GPNA, PNA 1pos:DNA
1 showed a negative salt dependence with increasing concentrations of NaCl. In con­
trast, PNA 1neg:DNA 1 showed a neutral salt dependence, providing preliminary evi­
dence that the presence of negative charge in PNA backbone can result in reversal of 
salt dependence for duplex formation.
Upon increasing the number of charged residues from one to three, a more pro­
nounced effect on Tm was observed (Figure 2.3b). As anticipated, the duplex stabilities 
of PNA 3neg and PNA 3pos with DNA 1 were greater than that of PNA nf with DNA 1,
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Figure 2.3. Tm vs [NaCl] for PNA:DNA 1 duplexes (a) PNA (nf/1neg/1pos): 
DNA 1, (b) PNA (nf/3neg/3pos):DNA 1, (c) PNA (nf/1Me/3Me):DNA 1.
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Figure 2.4. Tm vs [NaCl] for PNA:RNA 1 duplexes (a) PNA (nf/1neg/1pos): 
RNA 1, (b) PNA (nf/3neg/3pos):RNA 1, (c) PNA (nf/1Me/3Me):RNA 1.
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Table 2.2. Tm of PNA:DNA 1 duplexes at varying salt concentrations.*
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
PNA nf 46.3 ± 1.3 44.4 ± 0.8 43.7 ± 0.5 43.4 ± 0.3 42.4 ± 0.8 42.9 ± 0.8
PNA 1neg 45.8 ± 0.5 44.9 ± 0.8 44.9 ± 1.3 45.3 ± 1.5 45.4 ± 1.3 45.9 ± 0.8
PNA 3neg 43.6 ± 0.1 47.5 ± 0.9 46.5 ± 0.4 48.1 ± 0.3 48.1 ± 0.9 48.9 ± 0.7
PNA 1pos 56.0 ± 1.5 49.3 ± 0.9 48.5 ± 1.1 48.7 ± 0.9 47.7 ± 0.7 47.5 ± 0.4
PNA 3pos 61.6 ± 1.0 57.9 ± 0.4 52.3 ± 1.2 47.7 ± 1.5 47.1 ± 1.2 46.3 ± 1.2
PNA 1Me 52.2 ± 0.8 50.5 ± 0.8 49.8 ± 0.5 49.3 ± 0.5 48.8 ± 0.5 49.0 ± 0.3
PNA 3Me 43.2 ± 0.5 42.4 ± 0.6 42.7 ± 0.5 41.9 ± 0.8 40.5 ± 1.1 40.7 ± 1.5
*Conditions: 3 ^M PNA, 3 ^M DNA, 10 mM sodium phosphate buffer with added NaCl, 
pH 7.2. Errors represent standard deviation of three or four independent trials.
likely due to backbone preorganization by the y-substituents. Similar to PNA 1pos:DNA
1, PNA 3pos:DNA 1 showed a negative salt dependence with increasing NaCl concen­
tration. However, as we anticipated, incorporation of three negative charges resulted in a 
positive salt dependence for PNA 3neg:DNA 1, as this duplex is presumably able to take 
advantage of charge screening when cations are present. In the presence of only 10 mM 
sodium (from the sodium phosphate buffer), Tm values follow the order of PNA 
3pos>PNA nf>PNA 3neg, revealing the effect of unscreened electrostatic contributions. 
But, with added NaCl concentrations of 250 mM and above, PNA 3neg:DNA 1 surpris­
ingly becomes more stable than PNA 3pos:DNA 1 (Figure 2.3b and Table 2.2).
We were also curious to investigate the duplex stability of y-PNA having three 
neutral side chains (PNA 3Me). Although PNA 1Me demonstrated nearly identical Tm 
values to PNA 1pos, PNA 3Me showed Tm values even lower than those of PNA nf 
(Figure 2.3c and Table 2.2). These results are inconsistent with the well-known increase 
in Tm with an increasing number of y-substituents. We believe that these inconsistent Tm
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data are a result of the aggregation of PNA 3Me.
Duplex stability of charged PNA with RNA at varying salt concentrations
We next investigated the binding of charged PNA strands with complementary 
RNA. As was the case for DNA, incorporation of one or three y-substituted monomers in 
the PNA sequence increase the overall duplex stability with RNA (Figure 2.4 and Table 
2.3). Both PNA 1neg:RNA 1 and PNA 1pos:RNA 1 showed an initial decrease in Tm go­
ing from 0 to 50 mM NaCl, followed by a gradual increase in Tm up to 1 M NaCl (Figure 
2.4a). However, the Tm values of these two duplexes are the same within error at NaCl 
concentrations of 50 mM and above, indicating that the presence of a single charged 
residue has only minimal impact on PNA:RNA binding. Increasing the number of 
charged residues on PNA from one to three produced a more dramatic effect on RNA 
binding (Figure 2.4b).
Table 2.3. Tm of PNA:RNA 1 duplexes at varying salt concentrations.*
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
PNA nf 47.4 ± 0.6 46.4 ± 0.8 47.3 ± 1.0 47.1 ± 1.1 47.8 ± 1.0 48.5 ± 0.8
PNA 1neg 48.3 ± 0.5 46.9 ± 1.3 47.4 ± 1.3 48.5 ± 1.3 49.1 ± 1.3 53.5 ± 1.3
PNA 3neg 50.1 ± 0.7 52.5 ± 0.7 51.3 ± 0.4 53.5 ± 0.4 54.1 ± 0.9 55.8 ± 0.6
PNA 1pos 54.7 ± 1.3 46.9 ± 1.4 48.3 ± 1.5 49.5 ± 1.3 51.1 ± 1.2 52.1 ± 1.0
PNA 3pos 57.2 ± 0.8 54.6 ± 0.4 51.6 ± 1.1 48.0 ± 1.3 50.6 ± 1.0 50.9 ± 1.5
PNA 1Me 50.5 ± 1.3 50.1 ± 1.1 50.6 ± 1.1 51.6 ± 1.1 53.3 ± 0.9 54.0 ± 1.0
PNA 3Me 39.4 ± 0.8 40.9 ± 0.3 41.2 ± 0.1 42.6 ± 0.3 42.6 ± 0.6 43.9 ± 0.3
*Conditions: 3 ^M PNA, 3 ^M RNA, 10 mM sodium phosphate buffer with added NaCl, 
pH 7.2. Errors represent standard deviation of three or four independent trials.
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Analogous to the above described binding results of triply charged PNA with 
DNA, PNA 3pos:RNA 1 also displayed a negative salt dependence while PNA 
3neg:RNA 1 displayed a positive salt dependence. However, in the case of RNA, the 
threshold of negatively charged PNA to surpass positively charged PNA binding affinity 
was much lower at approximately 100 mM NaCl (Figure 2.4b and Table 2.3). As we ob­
served with DNA, PNA 1Me showed a higher duplex stability than PNA nf with RNA; but 
PNA 3Me showed a lower duplex stability than PNA nf (Figure 2.4c and Table 2.3), 
which we again attribute to possible aggregation.
Duplex stability of charged PNA with DNA and RNA under 
physiological salt conditions
Given the increasing use of PNA for in vivo applications, we sought to investigate 
the duplex stability of our charged PNA with DNA and RNA in a buffer that mimics 
physiological salt conditions (0.49 mM MgCl26H2O, 137 mM NaCl, 2.7 mM KCl, 1.5 mM 
KH2PO4, 8.1 mM Na2HPO4, pH 7.4)32 (Table 2.4). Consistent with previous 
observations, negatively charged PNA binds slightly more weakly with DNA than does 
positively charged PNA. However, in the case of RNA binding, negatively charged PNA 
was again superior to positively charged PNA when three charged substituents were 
present on the PNA backbone. These results reinforce the observations outlined above 
and lead to the unexpected conclusion that adding negative charge to PNA may in fact 
increase binding affinity in RNA-targeted antisense therapeutics.
Thermodynamic data analysis
The thermodynamic parameters for the interactions of PNA with nucleic acids 
can be calculated by van’t Hoff analysis of UV melting data and by calorimetric methods,
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Table 2.4. Tm of PNA:DNA 1 and PNA:RNA 1 duplexes under simulated physiological 
buffer conditions.*
Complement
Tm with DNA 1
(oC)
Tm with RNA 1
(oC)
DNA 2 37.2 ± 0.1 32.5 ± 0.8
PNA nf 43.2 ± 0.5 47.1 ± 1.1
PNA 1neg 45.9 ± 0.8 48.1 ± 1.1
PNA 1pos 46.9 ± 0.3 46.9 ± 0.8
PNA 1Me 47.3 ± 1.3 48.1 ± 1.5
PNA 3neg 46.1 ± 0.6 49.9 ± 1.5
PNA 3pos 49.1 ± 1.0 46.5 ± 1.7
PNA 3Me 40.0 ± 0.6 41.4 ± 0.6
*Conditions: 3 |jM PNA, 3 |jM DNA or RNA, 0.49 mM M g C h ^ O , 137 mM NaCl,
2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4. Errors represent standard de­
viation of three independent trials.
including isothermal titration (ITC) and differential scanning calorimetry (DSC).1 We per­
formed van’t Hoff analysis on the UV melting data to obtain the thermodynamic parame­
ters for duplex formation of PNA 3neg and PNA 3pos with DNA and RNA in physiologi­
cal buffer (Table 2.5).33,34 As expected, the Gibbs free energy change (AG) follows a 
similar trend as the Tm values for the duplexes, with higher free energy gain observed for 
duplexes having higher values of Tm. In duplex formation with DNA, PNA 3neg shows 
lower enthalpic driving force but also lower entropic cost, relative to PNA 3pos. Howev­
er, in the case of RNA duplex formation, the opposite is observed; PNA 3neg shows 
higher enthalpic driving force but higher entropic cost, relative to PNA 3pos.
The observed higher salt sensitivity of PNA:RNA duplexes can be attributed to 
the higher density of counterions associated with A-form structures than B-form struc­
tures. Thus, we hypothesize that the structural variation between PNA:DNA and 
PNA:RNA duplexes is responsible for the increased contribution of PNA backbone 
charge and NaCl concentration in PNA:RNA binding. This hypothesis is supported by
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Table 2.5. Thermodynamic parameters for the formation of duplexes of PNA 3neg and 
PNA 3pos with DNA and RNA.*
Duplex Tm (oC) AG (kJmol-1) AH (kJ mol-1) TAS (kJmol-1)
PNA 3neg:DNA 1 46.1 ± 0.6 -48.0 ± 0.3 -208.4 ± 1.0 -160.4 ± 1.0
PNA 3pos:DNA 1 49.1 ± 1.0 -49.8 ± 0.3 -213.2 ± 2.7 -163.4 ± 2.9
PNA 3neg:RNA 1 49.9 ± 1.5 -49.1 ± 0.8 -203.4 ± 3.6 -154.3 ± 2.9
PNA 3pos:RNA 1 46.5 ± 1.7 -47.9 ± 0.3 -191.5 ± 0.4 -143.6 ± 0.6
*Averages from van’t Hoff analysis of three trials of UV melting data. Errors represent 
standard deviation of three independent trials.
the thermodynamic data in Table 2.5, where the PNA 3neg:RNA duplex has greater en- 
thalpic gain with greater entropic cost, relative to the PNA 3pos:RNA duplex, as would 
be anticipated in the case of tight counterion binding to the PNA 3neg:RNA duplex. We 
are intrigued by the fact that the charged PNA:RNA duplexes do not follow a logarithmic 
trend for Tm as a function of ionic strength, as is the case for DNA: DNA and DNA:RNA 
duplexes.35
It should be noted that the Asp and Lys residues used for this initial study have a 
slight variation in side chain length. However, given the fact that the PNA:DNA helix di­
ameter is approximately 23 A ,17 and previous studies have reported that the Lys side 
chains are not involved in non specific charge-charge interactions,10 the two carbon dif­
ference in side chain length is anticipated to have little to no impact on duplex stability. 
Thus, we attribute the changes in duplex stability for negatively and positively charged 
PNA primarily to the differential electrostatic properties of these PNA strands.
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Conclusion
Given the hypothesis that the lack of electrostatic repulsion plays a key role in 
PNA binding, it is surprising to discover that adding negatively charged side chains to 
PNA does not significantly decrease binding affinity with DNA and RNA at physiological 
ionic strength. Moreover, because positively charged PNA displays negative salt de­
pendence and negatively charged PNA displays positive salt dependence, at medium to 
high salt concentrations, negatively charged PNA actually binds more strongly to DNA 
and RNA than does positively charged PNA. Presumably, preorganization of the PNA 
backbone via hydrogen bonding is primarily responsible for the enhanced duplex stability 
of PNA with DNA and RNA. This hypothesis has been previously reported in the litera­
ture,36,37 and recent studies by Ganesh and coworkers14 have demonstrated that addi­
tional backbone hydrogen bonding interactions can be used to further increase binding 
affinity or favor parallel versus antiparallel alignment of the nucleic acid strands. Future 
studies will utilize molecular dynamics simulations to provide greater insight into the ef­
fect of PNA charge on duplex structure.
In general, PNA:RNA duplexes are known to have higher thermal stabilities than 
PNA:DNA duplexes;1,16 yet our data shows that positively charged PNA:DNA duplexes 
have a higher thermal stability than positively charged PNA:RNA duplexes.21 This sug­
gests that careful modification of PNA may be used to modulate the selectivity of binding 
to DNA and RNA.38
The recent popularity of antisense therapeutics such as siRNA has prompted the 
development of a multitude of technologies aimed at enhancing the circulation lifetime 
and cell permeability of nucleic acids in vivo.39,4° However, nearly all of these technolo­
gies function on the basis of the negatively charged backbone found in native nucleic 
acids. Thus, the ability to impart negative charge to PNA without sacrificing binding affini­
ty with DNA and RNA may enable the development of therapeutics that are able to take
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advantage of the delivery technologies described above as well as the inherent benefits 
of PNA such as increased stability and enhanced binding affinity.41 This process would 
open the door to previously unexplored nucleic acid-delivery vector combinations and 
may lead to the discovery of antisense therapeutics with enhanced in vivo efficacy. This 
concept is further supported by the recent work of Romanelli and coworkers, in which 




Glassware for all reactions was oven dried or flame dried and cooled prior to use. 
All reactions were run under an atmosphere of nitrogen or argon unless otherwise stat­
ed. Tetrahydrofuran (THF) was distilled from sodium and benzophenone. Dichloro- 
methane (CH2Cl2) and dimethylformamide (DMF) were passed through a solvent purifi­
cation system (J. C. Meyer). Unless otherwise noted, all starting materials were obtained 
from commercial suppliers and were used without further purification. Thin layer chro­
matography was performed on Silica gel 60 F254 plates eluting with the solvent indicated, 
visualized by a 254/365 nm UV lamp, or stained with a solution of ninhydrin or potassium 
permanganate. Column chromatography was performed on Merck silica gel Kieselgel 60 
(230-400 mesh, 40-63 ^m particle size). Yields were calculated for material judged ho­
mogenous by thin layer chromatography and NMR. Compounds were named using CS 
ChemBioDraw Ultra 12.0. NMR spectra were acquired on a Varian Unity-300 or VXR 
500 spectrometer. Chemical shifts for 1H NMR spectra are reported in parts per million 
relative to the signal of residual CHCl3 at 7.27 ppm or the center line of the residual ace­
tone pentet at 2.05 ppm. Chemicals shifts for 13C NMR spectra are reported in parts per 
million relative to the center line of the CDCl3 triplet at 77.23 ppm or the center line of the
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acetone septet at 29.9 ppm. The abbreviations s, d, dd, t, q, m, br, and rot stand for sin­
glet, doublet, doublet of doublets, triplet, quartet, multiplet, broad, and rotamer respec­
tively. IR spectra were obtained from Nicolet 380 FT-IR spectrometer. Optical rotations 
were obtained at ambient temperature on a Perkin Elmer Model 343 polarimeter (Na D 
line) using a microcell with a 1 decimeter path length, and the reported concentrations 
(c) are in g/100 ml. Mass spectra were recorded at the Mass Spectrometry facility in the 
Department of Chemistry of the University of Utah. DNA/RNA was purchased from the 
University of Utah DNA/Peptide Synthesis Core Facility. Milli-Q water was obtained from 
Millipore Simplicity UV water purification system.
Oligomer synthesis
PNA oligomers were synthesized on NovaSyn TGR R resin (0.2 mmol/g) accord­
ing to published procedures using manual or semi-automated (Activo P-14 Peptide Syn­
thesizer) solid-phase peptide synthesis.27,42-45 The oligomers were cleaved from the res­
in using TFA:triisopropylsilane:H2O (95:2.5:2.5) cocktail. The resulting mixtures were 
precipitated with ether, purified by RP-HPLC (Agilent ZORBAX 300SB-C18, 5 ^M parti­
cle size, 9.4 x 250 mm) with a binary mixture of 0.1% TFA in water (eluent A) and 0.1% 
TFA in CH3CN (eluent B). The linear gradient was 8-18% of eluent B for 26 min at 50 °C 
at a flow rate of 4.0 mL/min. A small fraction of the purified compound was reinjected to 
RP-HPLC (Agilent ZORBAX 300SB-C18, 5 ^M particle size, 4.6 x 250 mm) for analysis. 
The linear gradient was 8-18% of eluent B for 26 min at 50 °C at a flow rate of 1.0 
mL/min. PNA strands were characterized by MALDI-TOF mass spectrometry in reflec- 
tron positive mode using a Waters Micromass MALDI Micro MX. The concentrations of 
the PNA oligomers were determined from the OD at 260 nm recorded in a UV-VIS Spec­
trophotometer (SHIMADZU 1800), using the extinction coefficient 100,300 M'1cm'1 for 
the sequence GTAGATCACT.
UV melting studies
The thermal melting studies were performed by using the temperature depend­
ence UV absorbance. All samples were prepared in buffer containing 10 mM sodium 
phosphate, pH 7.2, with added NaCl (0, 50, 100, 250, 500 1000 mM), except for the 
physiological buffer, which was 0.49 mM MgCl26H2O, 137 mM NaCl, 2.7 mM KCl, 
1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4. The samples were incubated at 95 oC for 
1 min, followed by gradual cooling to room temperature using a BioRad-MJ Mini Person­
al Thermal Cycler, before data collection. UV-Vis absorbance at 260 nm was recorded 
and corrected using the absorbance at 380 nm. The data were recorded at a rate of
1 oC/min, in 0.5 oC intervals, for both the heating (20-80 oC) and cooling (80-20 oC) runs 
(except PNA 3pos from 20-90 oC and reverse). The Tm values were determined by tak­
ing the first derivative of the cooling profiles, using Origin 8.5.1 software. Final Tm is an 
average of three or four independent trials, and error bars represent the standard devia­
tion.
Buffer preparation
Varying concentrations of NaCl were added to 10 mM phosphate buffer, pH 7.6, 
and initial pH measured. pH was adjusted to 7.2 using 6 M HCl or 5 M NaOH. The 
change of Na+ concentration in the buffer due to NaOH is equal to or less than 0.4%.
Thermodynamic analysis
The UV melting data were analyzed to obtain van’t Hoff transition enthalpies.33,34 
Baseline correction was applied to each plot of normalized absorbance vs temperature, 
providing plots of fraction melted (0) vs temperature. The thermodynamic parameters 
were determined by plotting ln Ka vs 1/T (van’t Hoff plot). Values of Ka, the affinity con­
stant, at each temperature were determined using the following equation for bimolecular,
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complementary oligonucleotides, where Co is the initial strand concentration.
e
For a two-state transition, if AH is independent of the temperature, then a plot of ln Ka vs 
1/T is linear, giving -AH/R as the slope and AS/R as the y-intercept. Gibbs free energy 
(AG) was calculated using the following equation, where T = 298 K.
(S)-tert-butyl3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-((2-(benzyloxy 
)-2-oxoethyl)amino)butanoate 2.4a. To a solution of aldehyde 2.3a24 (1.61 mmol) in 
CH2Cl2 (20 mL), glycine benzyl ester 4-toluenesulfonate (0.652 g, 1.93 mmol) and Et3N 
(0.67 mL, 4.8 mmol) were added at 0 °C. After stirring for 30 min, sodium triacetoxy- 
borohydride (0.444 g, 2.09 mmol) was added and the reaction mixture was stirred at rt 
for 16 h. The reaction mixture was quenched with sat. NaHCO3 (12 mL) and sat. Na2CO3 
(4 mL). After stirring for 30 min, the mixture was extracted with CH2Cl2 (3 x 30 mL). The 
combined organic extracts were washed with brine, dried over Na2SO4, and concentrat­
ed. The crude material was purified by silica flash column chromatography (1:1 
EtOAC:Hexane) to afford 0.526 g (60%, two steps from 2.2a) of the secondary amine 
2.4a as a pale yellow oil (Rf = 0.4 in 1:1 EtOAC:Hexane); [a]D25 = +0.4o (c 0.9, CH2Cl2); 
1H NMR (300 MHz, CDCl3) 5 7.67 (d, J = 7.4 Hz, 2 H), 7.54-7.5 (m, 2 H), 7.33-7.17 (m, 9
H), 5.54 (br d, J = 8.4 Hz, 1 H), 5.08 (s, 2 H), 4.31 (d, J = 6.7 Hz, 2 H), 4.14 (t, J = 6.7 
Hz, 1 H), 3.97 (br s, 1 H), 3.38 (d, J = 3.7 Hz, 2 H ), 2.78-2.62 (m, 2 H), 2.51-2.38 (m, 2





H), 1.88 (br s, 1 H), 1.37 (s, 9 H); 13C NMR (125 MHz, CDCfe) 172.2, 170.9, 156.1, 
143.8, 141.2, 135.5, 128.5, 128.32, 128.27, 127.6, 127, 125, 119.9, 81, 66.6, 64, 52, 
50.5, 50.1, 47.2, 37.2, 28; IR (neat): 3330, 2975, 1724, 1521, 1450, 1251, 1158 cm'1; 
HRMS (ESI) m/z for C32H36N2O6: 567.2477 (calcd [M+Na]+ 567.2471).
(S)-tert-butyl3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(N-(2-(benzyl 
oxy)-2-oxoethyl)-2-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamido)bu 
tanoate 2.5a. To a solution of thymine-1-acetic acid (0.059 g, 0.32 mmol), HATU (0.122 
g, 0.320 mmol) and 4 A MS in DMF (0.9 mL) at 0 °C, DIPEA (0.060 ml, 0.32 mmol) was 
added. After stirring at 0 °C for 15 min, a solution of secondary amine 2.4a (0.146 g, 
0.267 mmol) in CH2Cl2 (1.5 mL) was added and stirred at 0 °C for 10 min. After stirring 
at rt for 16 h, the reaction mixture was concentrated and washed with H2O. The aqueous 
layer was extracted with EtOAc (3x). The combined organic extracts were washed with 
sat. NH4Cl, sat. NaHCO3, and brine, dried over Na2SO4, and concentrated. The crude 
mixture was purified by silica flash column chromatography (a gradient of 
EtOAC:Hexane from 3:7 to 8:2) to afford 0.037 g (20%) starting secondary amine 2.4a 
and 0.097 g (51%) of amide 2.5a as a pale yellow oil (Rf = 0.5 in 8:2 EtOAC:Hexane);
[a]D25 = +5.5o (c 0.2, CH2Cl2); 1H NMR (500 MHz, CDCl3) 5 9.7 (s, 0.6 H, rot 1), 9.66 (s, 
0.4 H, rot 2), 7.62 (d, J = 7.7 Hz, 2 H), 7.49-7.46 (m, 2 H), 7.31-7.24 (m, 5 H), 7.23-7.15 
(m, 4 H), 6.83 (s, 0.6 H, rot 1), 6.73 (s, 0.4 H, rot 2), 6.27 (d, J = 8.4 Hz, 0.5 H, rot 1), 
5.81 (d, J = 8.4 Hz, 0.4 H, rot 2), 5.1 (s, 0.8 H, rot 1), 5.0 (s, 1.2 H, rot 2), 4.56 (s, 1 H, rot
o
2,5a
1), 4.34-4.22 (m, 3 H), 4.2-4.0 (m, 4 H), 3.6-3.4 (m, 2 H), 2.56-2.49 (m, 1.2 H, rot 1), 
2.44-2.34 (m, 0.8 H, rot 2), 1.73 (s, 1.7 H, rot 1), 1.72 (s, 1.3 H, rot 2), 1.34 (s, 5 H, rot
1), 1.32(s, 4 H, rot 2); 13C NMRmajor rotamer(125 MHz, CDCl3) 170.7, 169.1, 168.5, 168, 
156.4, 151.5, 144, 143.8, 141.4, 135.2, 128.9, 128.7, 128.3, 127.8, 127.2, 125.2, 120.1, 
110.7, 82, 67.3, 66.8, 51, 49.2, 47.9, 47.4, 47.2, 37.4, 28.1, 12.4; IR (neat): 3335, 2924, 







2.6a. To a solution of amide 2.5a (0.098 g, 0.14 mmol) in MeOH (5 mL) was added Pd/C 
(0.010 g) under N2. The flask was evacuated, then flushed with H2 gas. The reaction 
mixture was placed under H2 (balloon pressure). After stirring for 16 h, the reaction mix­
ture was filtered through a pad of Celite® and evaporated under reduced pressure to 
give 0.068 g (80%) of the modified peptide nucleic acid monomer 2.6a as a white solid 
(Rf = 0.1 in 9:1 CH2Cl2:MeOH); mp = 88-90 oC; [a]D25 = +2.4o (c 0.5, CH3OH); 1H NMR 
(500 MHz, acetone-d6) 5 10.67 (br s, 1 H), 7.82 (d, J = 6.8 Hz, 2 H), 7.66 (d, J = 4.9 Hz,
2 H), 7.38-7.23 (m, 5 H), 6.95 (br s, 0.5 H, rot 1), 6.7 (br s, 0.5 H, rot 2), 4.92-4.76 (br m, 
1 H), 4.59 (br s, 1.6 H, rot 1), 4.43 (br s, 0.4 H, rot 2), 4.38-4.32 (partially obscured br m,
1.4 H, rot 1,2), 4.28 (partially obscured br s, 1.6 H, rot 1), 4.24-4.1 (partially obscured br 
m, 2 H), 3.91 (dd, J = 6.8 Hz, 0.5 H, rot 1), 3.64-3.54 (partially obscured m, 1 H, rot 1,2),
3.39 (dd, J = 6.8 Hz, 0.5 H, rot 2), 2.6-2.48 (m, 2 H), 1.74 (br s, 3 H), 1.42 (s, 4 H, rot 1), 
1.39(s, 5 H, rot 2); 13C NMRmajor rotamer (125 MHz, acetone-d6) 171, 169.4, 168.8, 165.5, 
157.1, 152.5, 144.8, 143.1, 141.9, 128.5, 127.8, 124.9, 120.8, 110.3, 81.2, 67.4, 52 (br), 
49.2 (br), 48.4, 47.9, 47.8, 43, 28.2, 12.3; IR (neat): 2978, 1662, 1477, 1230, 1155 cm'1; 
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CHAPTER 3
DIFFERENTIAL DNA AND RNA SEQUENCE DISCRIMINATION 
BY PNA HAVING CHARGED SIDE CHAINS1 
Introduction
Peptide nucleic acid (PNA)1 is a nucleic acid mimic that shows excellent potential 
for use in therapeutic and biosensing applications, due to its high binding affinity and 
selectivity for DNA and RNA.2-4 PNA also benefits from excellent biostability, as the 
native nucleic acid sugar-phosphate backbone is replaced by an W-(2-aminoethyl)glycine 
unit.5 A number of modifications have been made to the PNA backbone to enhance 
binding affinity, cellular uptake, and solubility.6,7 Addition of side chains at the y-position 
of the PNA backbone has proven to be particularly successful, as this modification 
increases binding affinity by preorganizing the backbone,8 and enables a diverse range 
of chemical functionalities to be incorporated via simple amino acid building blocks.9,10
The Heemstra group is currently investigating PNAs having negatively charged y- 
substituents, as these would electrostatically mimic DNA and RNA, and thus likely be 
compatible with conventional nucleic acid delivery technologies. In Chapter 2, we 
explored the effect of ionic strength on binding affinity for PNA having either negatively 
charged aspartic acid side chains or positively charged lysine side chains.11 We 
observed that as ionic strength is increased, negatively charged PNA increases in
1 Reprinted from Bioorg. Med. Chem. Lett., 24, De Costa, N. T. S., Heemstra, J. M., Differential 
DNA and RNA Sequence Discrimination by PNA Having Charged Side Chains, 2360-2363,
Copyright (2014), with permission from Elsevier.
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affinity for DNA and RNA, whereas positively charged PNA decreases in affinity for DNA 
and RNA. Interestingly, the point at which these trends intersect hovers near 
physiological salt concentration. And, in simulated physiological buffer, negatively 
charged PNA shows slightly higher affinity for RNA whereas positively charged PNA 
shows slightly higher affinity for DNA.
Intrigued by the effect of side chain structure and electrostatics on binding 
affinity, we were also curious to explore the mismatch and orientation selectivity of these 
Y-substituted PNAs. In this chapter, we report that side chain structure also plays a 
surprising role in PNA binding selectivity. We find that introduction of Y-substituents 
results in similar or slightly decreased selectivity compared to unmodified PNA. 
However, for Y-substituted PNAs, positively charged side chains provide higher 
selectivity in DNA binding and negatively charged side chains provide higher selectivity 
in RNA binding.12
Results and Discussion 
Structure and sequence of modified PNA strands
To investigate the role of side chain structure and electrostatics on sequence 
selectivity, we utilized our previous Y-functionalized sequences, PNA 3neg and PNA 
3pos (Figure 3.1).11,12 These sequences have three aspartic acid or lysine side chains, 
respectively, distributed across the well-studied Nielsen decamer sequence (Table 3.1).4 
The thermal melting stability of PNA 3neg, PNA 3pos, and unmodified PNA nf with 
complementary, single base mismatched, and parallel DNA and RNA sequences under 
simulated physiological salt conditions were measured. The complementary, antiparallel 
DNA 1 and RNA 1 sequences contain X=A, whereas the mismatched sequences contain 
X=G, C, or T/U. The mismatch was introduced in the middle of the sequence,13
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Figure 3.1. Chemical structure of y-substituted PNA monomers.
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and was positioned opposite a y-functionalized PNA monomer, as this was anticipated to 
maximize the impact of side chain structure on duplex stability. Sequences DNA 2 and 
RNA 2 are fully complementary to the PNA strands, but form duplexes in the less stable 
parallel orientation. The mismatch and orientation selectivity of y-PNA having three 
neutral side chains (PNA 3Me) were not examined; as discussed in Chapter 2, due to 
the unreliable data, which likely resulted from the aggregation of the sample.
The effect of side chain structure on mismatch and 
antiparallel versus parallel discrim ination
We first investigated the effect of side chain structure on mismatch and 
antiparallel versus parallel discrimination in PNA:DNA duplexes. As shown in Figure 
3.2a and Table 3.2a, PNA nf and PNA 3pos showed similar levels of duplex 
destabilization after the introduction of a single base mismatch or reversal of strand 
orientation. However, the selectivity of PNA 3neg is significantly lower, as evidenced by 
the smaller net ATm values. In the case of PNA:RNA duplexes, we found that the effects 
of side chain electrostatics were reversed, as PNA nf and PNA 3neg show similar levels 
of duplex destabilization upon introduction of a single base mismatch or reversal of 
strand orientation, and as the selectivity of PNA 3pos is significantly lower (Figure 3.2b, 
Table 3.2b). In previous work by Ly and coworkers, positively charged guanidinium 
PNAs (GPNAs) have also exhibited a similar trend in binding by having a greater 
destabilization for most of the mismatched DNA over RNA sequences.14
Previous studies have been performed to understand the unmodified PNA:DNA 
sequence selectivity, in terms of best and worst mismatched base pairs, but data are 
quite contradictory at times since the impact created by mismatches varies with the 
contexts.13 We were also curious to see whether the variation in the mismatched base 
from X=G, C, or T/U showed any significant trend. In comparing the identity of the 
mismatched base and the ATm, we expected that X=G would result in a smaller duplex 
destabilization than X=C or X=T/U, as the T:G mismatch can still form a wobble base 
pair.13,15,16 The data in Figure 3.2 show that this is the case for the PNA:RNA duplexes, 
but the PNA:DNA duplexes show a relative insensitivity to the identity of the mismatched 
base. Previous studies have observed quite inconsistent results for T:T mismatch, with 




X = G X = C X = T DNA 2
■  PNA nf ■  PNA 3neg ■ PNA 3pos
Complementary RNA strand
X = G X = C X = U RNA 2
■ PNA nf ■  PNA 3neg l_PNA3pos
Figure 3.2. Comparative ATm values of duplexes of PNA 
(nf/3neg/3pos) with mismatched and parallel sequences of 
(a) DNA and (b) RNA.
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Table 3.2. Tm (oC) of (a) PNA:DNA and (b) PNA:RNA duplexes under simulated 
physiological buffer conditions.*
(a) DNA 1 DNA 1 DNA 1 DNA 1 DNA 2
A)=(X (X = G)
O
=(X (X = T)
PNA nf 43.0 ± 0.7 32.5 ± 0.1 36.2 ± 0.3 32.5 ± 0.7 31.7 ± 1.5
PNA 3neg 46.3 ± 0.7 40.6 ± 0.3 40.8 ± 1.0 42.6 ± 1.4 43.2 ± 0.8
PNA 3pos 49.1 ± 1.0a 38.6 ± 1.3 37.9 ± 0.4 39.0 ± 0.7 40.0 ± 1.3
(b) RNA 1 RN A 1 RNA 1 RNA 1 RNA 2
(X = A) (X = G) (X = C) (X = U)
PNA nf 47.1 ± 1.1 a 36.6 ± 0.4 28.5 ± 0.7 28.5 ± 0.7 31.2 ± 1.2
PNA 3neg 49.9 ± 1.5 a 40.0 ± 1.3 30.3 ± 1.0 34.0 ± 0.8 39.0 ± 1.1
PNA 3pos 46.5 ± 1.7 a 40.8 ± 1.3 38.4 ± 0.7 37.1 ± 1.2 39.7 ± 0.7
Conditions: 3 |jM PNA, 3 |jM DNA or RNA, 0.49 mM MgCl26H2O, 137 mM NaCl, 
2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4. Errors represent standard 
deviation of three independent trials. aFrom Chapter 2.
stacking (size).13 We observed T:T mismatch to be the most unstable in all three 
PNA:RNA duplexes, but only for some PNA:DNA duplexes.
Previous studies conducted on PNAs having neutral or positively charged y- 
substituents have shown that modified PNAs have similar or improved selectivity relative 
to unmodified p n a .8-10,14,16-19 The data presented here deviate from this trend, as in 
most cases PNA nf shows equal or higher binding selectivity relative to the y-substituted 
PNAs. One potential source of this difference is the number of y-substituents present in 
our PNA sequences. However, in the previous reports, substitution densities ranging 
from 1 to 10 substituents over a 10-mer sequence were investigated. Thus, it is unlikely 
that our choice of sequences having 3 substituents is the source of the observed 
deviation. Since previous studies investigated PNA strands having a structurally-diverse 
range of side chains,8'10,14,16'19 our specific choices of aspartic acid and lysine are likely 
not the source of the observed deviation. Rather, in nearly all of the previous studies, 
duplex stability was measured at ionic strengths that were significantly weaker than the 
physiological salt conditions used in the current study. In fact, the studies which used
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the lowest ionic strength resulted in the greatest observed selectivity for Y-substituted 
PNA relative to unmodified PNA.16,18,19
We and others have previously observed that ionic strength plays a significant 
role in PNA:DNA and PNA:RNA duplex stability,11,20 and for unmodified PNA, the highest 
stability is observed at the lowest ionic strength due to the polyelectrolyte behaviour of 
PNA duplexes. The stability of a mismatched PNA:DNA duplex is nearly the same at low 
and high ionic strengths. However, the presence of mismatches prevent the duplex 
stabilization at low ionic strength, thus sequence selectivity with DNA has been shown to 
be highest at low ionic strength.21,22 Hence, we hypothesize that the relatively higher 
ionic strength of the simulated physiological buffer is primarily responsible for the 
difference between our results and those reported in previous studies.
Thermodynamic data analysis
Thermodynamic parameters for duplex formation of PNA 3neg and PNA 3pos 
with DNA and RNA were derived using van’t Hoff analysis of the UV thermal melting 
data (Tables 3.3-3.6).23 As expected, the calculated AG values mirror the measured Tm 
values for each duplex, with reduced Gibbs free energy gain in duplexes having lower 
values of Tm. In general, duplex formation with mismatched or parallel sequences 
experienced a lower enthalpic driving force; but this was partially compensated for by a 
reduced entropic cost, except for the PNA 3pos:RNA duplexes with X=G and RNA 2. 
This result is logical, as the introduction of mismatches reduces the enthalpy gained 
from Watson-Crick base-pairing interactions, and the conformational freedom gained 
from loss of these interactions would be expected to be entropically favorable.13 This 
enthalpy-entropy compensation could result from combined effects of interruption of
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Table 3.3. Thermodynamic parameters for the formation of duplexes of PNA 3neg with 
DNA.*
Duplex Tm (oC) AG (kJ^mol-1) AH (kJ^mol-1) TAS (kJ^mol-1)
DNA 1 (X = A) 46.3 ± 0.7 -48.0 ± 0.1 -200.2 ± 6.2 -152.2 ± 6.2
DNA 1 (X = G) 40.6 ± 0.3 -45.6 ± 0.1 -151.4 ± 5.3 -105.7 ± 5.1
(-5.7) (2.4) (48.8) (46.5)
DNA 1 (X = C) 40.8 ± 1.0 -46.2 ± 0.5 -167.7 ± 15.7 -121.5 ± 15.2
(-5.5) (1.8) (32.5) (30.7)
DNA 1 (X = T) 42.6 ± 1.4 -45.9 ± 0.3 -175.1 ± 9.4 -129.2 ± 9.3
(-3.7) (2.1) (25.1) (23.0)
DNA 2 43.2 ± 0.8 -46.4 ± 0.2 -172.7 ± 12.6 -126.3 ± 12.4
(-3.1) (1.6) (27.5) (25.9)
Table 3.4. Thermodynamic parameters for the formation of duplexes of PNA 3pos with 
DNA.*
Duplex Tm (°C) AG (kJ^mol-1) AH (kJ^mol-1) TAS (kJ^mol-1)
DNA 1 (X = A) 49.1 ± 1.011 -50.2 ± 0.4 -217.0 ± 2.1 -166.8 ± 2.2
DNA 1 (X = G) 38.6 ± 1.3 
(-10.5)
-44.9 ± 0.4 
(5.3)
-162.9 ± 5.5 
(54.1)
-118.0 ± 5.2 
(48.8)
DNA 1 (X = C) 37.9 ± 0.4 
(-11.2)
-44.8 ± 0.2 
(5.4)
-183.3 ± 14.1 
(33.7)
-138.5 ± 14.1 
(28.3)
DNA 1 (X = T) 39.0 ± 0.7 
(-10.1)
-45.2 ± 0.3 
(5.0)
-177.2 ± 7.1 
(39.8)
-132.0 ± 6.9 
(34.8)
DNA 2 40.0 ± 1.3 
(-9.1)
-45.7 ± 0.4 
(4.5)
-188.5 ± 4.4 
(28.5)
-142.8 ± 4.4 
(24.0)
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Table 3.5. Thermodynamic parameters for the formation of duplexes of PNA 3neg with 
RNA.*
Duplex Tm (°C) AG (kJ^mor1) AH (kJ^mol'1) TAS (kJ^mol'1)
RNA 1 (X = A) 49.9 ± 1.511 -49.7 ± 0.9 -211.3 ± 5.1 -161.6 ± 4.3










4 - -197.9 ± 13.3 
(13.4)
-152.2 ± 13.4 
(9.4)
RNA 1 (X = C) 30.3 ± 1.0 
(-19.6)
-41.2 ± 0.1a 
(8.5)
-125.5 ± 1.2 a 
(85.8)
-84.4 ± 1.3 a 
(77.2)
RNA 1 (X = U) 34.0 ± 0.8 
(-15.9)
-42.0 ± 0.4b 
(7.7)
-128.6 ± 6.9 b 
(82.7)
-86.6 ± 6.5 b 
(75.0)
RNA 2 39.0 ± 1.1 
(-10.9)
-45.1 ± 0.5 
(4.6)
-147.3 ± 9.7 
(64.0)
-102.2 ± 9.3 
(59.4)
Data were calculated over a temperature range of a7-85 oC and b15-85 oC.
Table 3.6. Thermodynamic parameters for the formation of duplexes of PNA 3pos with 
RNA.*
Duplex Tm (°C) AG (kJ^mol'1) AH (kJ^mol'1) TAS (kJ^mol'1)
RNA 1 (X = A) 46.5 ± 1.711 -47.6 ± 0.8 -186.2 ± 6.0 -138.5 ± 5.3
RNA 1 (X = G) 40.8 ± 1.3 
(-5.7)
-46.2 ± 0.5 
(1.4)
-203.2 ± 0.8 
(-17.0)
-157.0 ± 0.3 
(-18.5)





















RNA 1 (X = U) 37.1 ± 1.2 
(-9.4)
-45.9 ± 0.5 
(1.7)
-158.3 ± 5.2 
(27.9)
-112.4 ± 5.7 
(26.1)
RNA 2 39.7 ± 0.7 
(-6.8)
-45.5 ± 0.4 
(2.1)
-187.6 ± 4.4 
(-1.4)
-142.1 ± 4.1 
(-3.6)
*Averages from van’t Hoff analysis of UV melting data. Errors represent standard 
deviation of three or four independent trials. Red colored values in parenthesis represent 
the difference with respect to the matched, antiparallel sequence.
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base pair formation and stacking, as well as rearrangement of solvent molecules and 
ions.
The effect of varying the position o f the mismatch site relative 
to the side chains on mismatch discrim ination
In an effort to study the generality of the observed trends, we shifted the 
mismatched base by one position, so that it was still in the middle of the duplex but 
opposite an unmodified PNA monomer. We chose to investigate the A:C mismatch at 
this position, as this was the most suitable mismatched pair for direct comparison to the 
data in Table 3.2. The complementary, antiparallel DNA 3 and RNA 3 sequences contain 
Y=T/U, whereas the mismatched sequences contain Y=C. We found that again PNA 
3pos showed higher selectivity for DNA and PNA 3neg showed higher selectivity for 
RNA (Table 3.7).
Table 3.7. Tm data (oC) of PNA:DNA 3/RNA 3 duplexes under simulated 
physiological salt conditions.*
Tm with DNA (oC) Tm with RNA (oC)
DNA 3 DNA 3 RNA 3 RNA 3
T)=(Y (Y = C) (Y = U) (Y = C)
PNA nf 43.0 ± 0.7 32.7 ± 1.0 (-10.3) 47.1 ± 1.1a
30.1 ± 1.0 
(-17.0)
PNA 3neg 46.3 ± 0.7 44.3 ± 0.7 (-2.0) 49.9 ± 1.5a
37.9 ± 0.4 
(-12.0)
PNA 3pos 49.1 ± 1.0a 38.1 ± 1.4 (-11.0) 46.5 ± 1.7a
36.0 ± 0.4 
(-10.5)
"Conditions: 3 |jM PNA, 3 |jM DNA or RNA, 0.49 mM MgCl26H2O, 137 mM NaCl, 
2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4. Errors represent standard 
deviation of three independent trials. aFrom Chapter 2.
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Structural analysis by circular dichroism (CD) spectroscopy
We initially hypothesized that the difference in selectivity between PNA 3neg and 
PNA 3pos may be due to differences in duplex structure caused by the charged side 
chains. Using CD spectroscopy, we first analysed each of the PNA strands alone in 
simulated physiological buffer conditions (Figure 3.3). As expected, achiral PNA nf 
shows no CD signal; but y-modified PNAs 3neg and 3pos show maxima at 220 and 
260 nm and minima at 210 and 240 nm respectively, indicative of preorganization into a 
right-handed helix.8,9,24 All three PNA:DNA duplexes show similar CD spectra, with peak 
shapes and wavelengths (maxima at ~275 nm and minima at ~240 nm) characteristic of 
a B-form helix; and all three PNA:RNA duplexes show similar CD spectra, with peak 
shapes and wavelengths (maxima at ~260 nm and minima at ~210 nm) characteristic of 
an A-form helix (Figure 3.4 and 3.5).4 This result was unexpected, given the 
dramatically different mismatch selectivity of PNAs 3neg and 3pos. However, we 
hypothesize that the charged side chains may still give rise to local structural 
perturbations, which could impact selectivity without significantly altering the overall CD 
spectrum. We are currently pursuing computational studies in an attempt to gain more 
detailed insight into the impact of the charged side chains on PNA:DNA and PNA:RNA 
duplex structure.
Conclusion
The results discussed here is the first to directly compare sequence selectivity for 
y-modified PNAs having positively or negatively charged side chains. For these 
y-modified PNA strands, PNA 3pos shows superior binding selectivity with DNA; and 
PNA 3neg shows superior binding selectivity with RNA. CD studies reveal that the side 
chains do not significantly alter the overall structure of the PNA:DNA or PNA:RNA
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2 ----- PNA nf
PNA 3neg 
PNA 3pos
Figure 3.3. CD spectra of PNA (nf/3neg/3pos) under simulated 
physiological buffer conditions.
(Conditions: 10 j M PNA, 0.49 mM MgCl26H2O, 137 mM NaCl, 2.7 mM 
KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4, 20 oC).
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Figure 3.4. CD spectra of PNA (nf/3neg/3pos) with complementary (a) DNA 1 
and (b) RNA 1 under simulated physiological buffer conditions.
(Conditions: 5 |jM PNA, 5 |jM DNA or RNA, 0.49 mM MgCl26H2O, 137 mM 
NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4, 20 oC).
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Figure 3.5. Representative CD spectra overlap to demonstrate the 
structural variations of single stranded y-PNA and y-PNA in duplex 
formation with DNA and RNA.
duplexes. However, they may still provide sufficient local perturbation to account for the 
observed differences in selectivity. It should be noted that the aspartic acid and lysine 
monomers used in this initial study have slightly different side chain lengths. In lysine 
monomer, the charged atom is two carbons away from the PNA backbone compared to 
aspartic acid monomer. This may have a minor impact on counterion binding and 
backbone hydration, but data from our previous study support the hypothesis that the net 
charge of the backbone is the prevailing factor in determining duplex stability.11
y-PNAs structural stability is influenced by the tri-centered backbone-water- 
nucleobase interactions. Specifically, the availability of numerous donor and acceptor 
sites in the backbone may further impact the solvent interactions.25 We hypothesize that 
the functionality in the incorporated y-side chains together with the variations in structure 
of native nucleic acids could influence the solvation network, H-bonding, and cation- 
binding interactions; hence resulting in differential binding properties and sequence 
recognition of side chain functionalized PNAs.
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Thus, in the development of y-substituted PNA strands for specific biological 
targets, it may be important to investigate the selectivity of each individual sequence. 
Additionally, our results highlight the potential importance of investigating PNA binding 
affinity and selectivity under physiological conditions when biological applications are 
anticipated. Together, this research provides insight into the surprising impact of side 
chain structure on binding selectivity for y-substituted PNA, and suggests that the ideal 
side chains for PNA:DNA duplex formation may be different from those that are ideal for 
PNA:RNA duplex formation. We anticipate that PNA together with its enhanced 
sequence specificity and differential binding ability would play a revolutionary role in the 
detection of single point mutations.
This work highlights that the variation of functional group in the y-position allows 
differential binding tendency toward nucleic acids. Future studies in spectroscopic, 
crystallographic, and computational fields are required to fully understand our findings. 
Future investigations are also needed to explore the effect of side chain length on duplex 
stability and mismatch discrimination. While we do observe that side chain structure and 
electrostatics are the prevailing factors in determining selectivity, the positioning of the 
side chains relative to the mismatch site may also have a subtle impact. Also, further 
work is needed to understand the effect of numerous side chains, sequences, and 
sequence lengths on mismatch discrimination of y-substituted PNAs.
Experimental Section 
General techniques
DNA/RNA was purchased from the University of Utah DNA/Peptide Synthesis 
Core Facility. Mass spectra were recorded at the Mass Spectrometry facility in the 
Department of Chemistry of the University of Utah. Milli-Q water was obtained from
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Millipore Simplicity UV water purification system.
UV melting studies
All samples were prepared in buffer containing 0.49 mM MgCl26H2O, 137 mM 
NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4.26 The samples were 
incubated at 95 oC for 1 min, followed by cooling to room temperature at a rate of 0.1 
oC/sec using a BioRad-MJ Mini Personal Thermal Cycler, before data collection. UV-Vis 
absorbance at 260 nm was recorded and corrected using the absorbance at 380 nm (UV 
cell path length = 1 cm). The data were recorded at a rate of 1 oC/min, in 0.5 oC 
intervals, for both the heating and cooling runs. The Tm values were determined by 
taking the first derivative of the cooling profiles (85-20 oC), using Origin 8.5.1 software. 
Final Tm is an average of three or four independent trials, and error bars represent the 
standard deviation.
Thermodynamic analysis
The UV melting data were analyzed to obtain van’t Hoff transition enthalpies.23,27 
Baseline correction was applied to each plot of normalized absorbance versus 
temperature (over 20-85 oC range), providing plots of fraction melted (0) versus 
temperature. The thermodynamic parameters were determined by plotting ln Ka vs 1/T 
(van’t Hoff plot). Values of Ka, the affinity constant, at each temperature were determined 
using the following equation for bimolecular, non-self-complementary oligonucleotides, 
where Co is the initial strand concentration.
9
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In order to have a precise Ka, 0 values lying in the range of O.15<0<O.85 are
taken for the van’t Hoff plot. For a two-state transition, if AH is independent of the 
temperature, then a plot of ln Ka vs 1/T is linear, giving -AH/R as the slope and AS/R as 
the y-intercept. Gibbs free energy (AG) was calculated using the following equation, 
where T = 298.15 K.
AG = AH -  TAS
Circular dichroism (CD) analysis
CD spectra were recorded on JASCO J815 CD spectrometer. All samples were 
prepared in a buffer containing 0.49 mM MgCl26H2O, 137 mM NaCl, 2.7 mM KCl,
1.5 mM KH2PO4, 8.1 mM Na2HPO4, pH 7.4.26 The samples of PNA:DNA/RNA duplexes 
were incubated at 95 oC for 1 min, followed by cooling to room temperature at a rate of 
0.1 oC/sec using a BioRad-MJ Mini Personal Thermal Cycler, before data collection. All 
CD spectra were recorded at 20 °C in the range 200-320 nm (cell path length =
1.00 mm). Final spectra are an average of 10 scans, which were scanned at a speed of 
100 nm/min. Buffer data was subtracted from the sample data, which was then 
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CHAPTER 4
TOW ARD DNA-TEMPLATED PNA POLYMERIZATION USING  
DYNAMIC COVALENT CHEMISTRY
Introduction
Nucleic acid-templated polymerization translates genetic information into 
functional macromolecules and allows the evolution of biopolymers.1 The molecular 
recognition capability of oligonucleotides can be used to direct the programmable 
assembly of reactive partners to engage in chemical reactions.2 Groundbreaking work by 
the Gilham3 and Orgel4 groups revealed that oligonucleotide templates can drive the 
ligation of complementary strands having activated phosphodiesters. This pioneering 
work, together with the curiosity to unveil the mysteries of prebiotic chemistry, has driven 
the exploration of various template-driven chemical reactions. Significant progress has 
been achieved with translating information from oligonucleotide sequences into 
functional materials and novel architectures (conductive polymers, nanopatterns), 
fluorescent or bioactive molecules, and synthetic polymers.2,5
In template-driven reactions, the spontaneous reaction between unbound 
reactants is inhibited in the absence of the template. In the presence of the template, the 
effective concentrations of the reactive partners are increased upon binding, thereby 
increasing the rate of the reaction.2 Numerous chemical functionalities and reactions 
have been investigated in template driven systems. Nucleic acid-templated reactions 
can be divided into three types, (1) templated inter-strand crosslinking, (2) templated 
strand ligation, and (3) templated transformation without ligation (Figure 4.1).2
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Photocrosslinking via [2+2] cycloaddition
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b) Templated strand ligation
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Figure 4.1. Three types of nucleic acid-templated reactions with representative 
examples [adapted with permission from (Gorska, K.; Winssinger, N. Angew. Chem. Int. 
Ed. 2013, 52, 6820-6843), copyright © (2013) WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim].
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"Inter-strand crosslinking” approaches have been used for the selective capturing 
of complementary strands, followed by light or oxidant-induced crosslinking (Figure 
4.1a). These are utilized in applications such as single-nucleotide polymorphism (SNP) 
detection.6 The second approach, "templated ligation” was the first nucleic acid- 
templated reaction to become popular because of its relevance to the origin of life as 
templated ligations are required for the enzyme free amplification of genetic material. 
Thus, numerous efficient, orthogonal, and biocompatible templated ligations have been 
studied based on reactions such as photoligation, azide-alkyne cycloaddition,7,8 
nucleophilic substitution, and condensation (Figure 4.1b).2 These ligation chemistries 
have been used in applications including SNP detection, generation of fluorogenic 
probes,9 and construction of sophisticated nanostructures such as catenanes,10 
dendrimers, G-quaduplexes, and conducting polymers.2 The third type of templated 
reaction, "templated transformations” , are required for the synthesis of functional 
molecules (proteins) using the information encoded in the nucleic acid sequences 
(Figure 4.1c). Various templated transformation reactions, such as templated hydrolysis, 
acyl transfer, azide reduction,11,12 and Wittig reaction, have been investigated (Figure 
4.2a).2 Interestingly, the Liu group performed one-pot, six-step, DNA-templated 
synthesis utilizing this method (Figure 4.2b).13
In fact, one of the ultimate goals of the aforementioned nucleic acid-templated 
reactions is to find a suitable method to translate information encoded in a DNA 
sequence into an evolvable synthetic polymer. In particular, the ability of biopolymers to 
translate from DNA and RNA, and then mutate and evolve allows them to expand their 
potential, performing functions essential for life. As discussed previously, the use of 
natural polymers in numerous applications is limited due to their stability, bioavailability, 
and immunogenicity. Artificial polymers can be tailored to overcome the above 
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Figure 4.2. Selected applications of nucleic acid-templated reactions (a) fluorogenic 
probes,* (b) six-step DNA-templated synthesis.** [*Adapted with permission from 
(Franzini, R. M.; Kool, E. T. J. Am. Chem. Soc. 2009, 131, 16021-16023), copyright © 
(2009) American Chemical Society. **Reprinted with permission from (Gorska, K.; 
Winssinger, N. Angew. Chem. Int. Ed. 2013, 52, 6820-6843), copyright © (2013) WILEY- 
VCH Verlag GmbH & Co. KGaA, Weinheim].
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are limited to biopolymers. Therefore, the evolution of abiotic polymers, including PNA,16 
requires methods for sequence encoding and amplification. Towards this endeavor, 
polymerase catalyzed templated synthesis of nucleic acids with modified bases and 
backbone-modified nucleic acid analogues, such as oligonucleotides of 
phosphorothioates, phosphoramidates, 2’-modified ribose, TNA (threose nucleic acid),17 
HNA, GNA, and LNA have been investigated.1 In addition, protein synthesis by 
ribosomal machinery has been mimicked to generate artificial peptides and 
polyesters.18,19 However, the structural and functional diversity of nonnatural polymers 
derived from biosynthetic pathways is limited by the need for compatibility with 
polymerases or the ribosome.1
Nonenzymatic, templated polymerization allows for the generation of sequence- 
defined, genetically-encoded synthetic polymers having desired functional properties. 
Nonenzymatic ligation of hexitol and altritol nucleic acids has been investigated, but the 
polymerization was limited to only tetramers.1 Also, PNA-templated RNA polymerization 
has been examined, but suffers from regioselectivity issues in polymerization. Lynn and 
coworkers expanded the substrate scope of nonenzymatic ligations by introducing 
amine-DNA and amido-DNA, in which reductive amination was used as an alternative 
strategy for polymerizations that do not contain phoshodiester linkages.1,20
Recently, the Liu group has put forth strategies to overcome the limitations of 
nonenzymatic, templated polymerization by taking advantage of PNA in DNA-templated 
polymerizations.1,21-23 The favorable stability and affinity of PNA together with 
speculation of its prebiotic relevance has made PNA an attractive tool for templated 
polymerizations.24 Early studies of DNA-templated PNA polymerization used amine 
acylation as the coupling reaction.25 Based on the pioneering work by the Lynn group, 
the Liu group demonstrated the condensation of PNA oligomers under reductive 
amination conditions.21 Reductive amination conditions are advantageous over acylation
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conditions, as the initial imine intermediate forms reversibly, thus driving the assembly of 
the oligomers of fully complementary sequence.
The Liu group tested the templated ligation of PNA fragments containing one or 
multiple side chains at various positions to generate a 40-mer PNA, having 24 side-chain 
modifications.22 This innovation opens up potential applications of nonenzymatic 
translation of nucleic acid sequences to multifunctional synthetic polymers. They further 
ensured the success of this method by presenting both the transcription of DNA 
templates to synthetic PNA polymers, as well as a method for selection, amplification, 
and retranscription of these PNA sequences.26 Although significant work has been done 
related to DNA-templated PNA polymerization, all of the previous systems utilized 
polymerization between small blocks of oligomers, rather than single monomers.
As an alternative to templated polymerization via backbone ligation, the groups of 
Liu23 and Ghadiri27 concurrently reported a base-filling approach, in which nucleobases 
were added to a preformed abasic PNA backbone (Figure 4.3). In the method reported 
by the Liu group, four nucleobase aldehydes or acids were incubated into PNA duplexes 
having an abasic site, and subsequently subjected to reductive amination conditions or 
carboxylic acid activation conditions.23 They were able to successfully isolate the 
complementary base-filled PNA duplex with high yield and selectivity under reductive 
amination conditions. The method reported by Ghadiri group utilized a trans- 
thioesterification between cysteine residues in an abasic peptide backbone and 
nucleobase thioesters.27
Dynamic covalent chemistry is defined as chemical ligation reactions that are 
carried out reversibly under equilibrium control.28 This reversible nature of the reactions 
allows error checking and proofreading, thus yielding the more thermodynamically stable 
final product. Although numerous dynamic covalent chemical reactions have been 
investigated in supramolecular assembly systems, our interest was drawn towards the
81
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Figure 4.3. Templated polymerization via base filling [adapted from (ACS 
AuthorChoice article: Heemstra, J. M.; Liu, D. R. J. Am. Chem. Soc. 2009, 131, 11347­
11349) and (Ura, Y.; Beierle, J. M.; Leman, L. J.; Orgel, L. E.; Ghadiri, M. R. Science
2009, 325, 73-77, with permission from AAAS)].
thiolactone exchange zip-reaction,29 as thioesters are ubiquitous in nature and also 
postulated as precursors to life.30
Previous work by the Seitz group utilized native chemical ligation (NCL) for the 
coupling of PNA fragments.31,32 They achieved higher yield and turnover rates when 
using PNA fragments containing isocysteine at the N-terminus and glycine thioesters at 











Figure 4.4. Templated native chemical ligation of PNA [adapted with permission from 
(Gorska, K.; Winssinger, N. Angew. Chem. Int. Ed. 2013, 52, 6820-6843), copyright © 
(2013) WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim].
the NCL strategy to achieve rapid, robust reactions with high turnover rates.32 In some 
instances, nontemplated hydrolysis of the thioester led to background signal, but careful 
optimization of conditions allowed for these limitations to be overcome.32 Additionally, as 
we mentioned above, the Ghadiri group used a trans-thioesterification between cysteine 
residues in an abasic peptide backbone and nucleobase thioesters in their base-filling 
method.27
In an attempt to achieve single-nucleotide templated polymerization, we 
designed the PNA monomer 4.1 that can take advantage of the reversible thiol- 
thiolactone ring opening reaction (Figure 4.5). We anticipate that the dynamic nature of 
the ligation chemistry will allow the editing of misincorporated nucleotides, analogous to 
the exonuclease activity of polymerases. Our current research on this project mainly 
involves the synthesis of modified PNA monomer 4.1. Outlined here in the fourth chapter 
of this dissertation are studies directed toward the synthesis of the modified PNA 
monomer. Upon synthesis of the monomer, the ability of base pairing and base stacking 
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Figure 4.5. Proposed DNA-templated PNA polymerization via thiol-thiolactone ring 
opening method.
Results and Discussion 
Retrosynthesis
We initially planned on synthesizing the modified PNA monomer via two different 
approaches, a convergent route and linear route. In the convergent route, it was 
envisioned that the desired cyclic monomer 4.1 would arise from amide bond formation 
between diaminopurine acetic acid 4.2 and thiomorpholinone 4.3 (Scheme 4.1). 
Thiomorpholinone 4.3 would be obtained from disulfide bond cleavage of dimer 4.4 
followed by thioesterification. Alkylation of the amines of cystamine dihydrochloride 4.5 
with bromoacetyl ester would give 4.4.
In the linear route, it was envisioned that the cyclic monomer 4.1 would arise 
from thioesterification of modified PNA backbone 4.6, which would be obtained from 
disulfide bond cleavage of dimer 4.7 (Scheme 4.2). The alkylation of cystamine 
dihydrochloride 4.5 with bromoacetyl ester, followed by amide bond formation with 












































Scheme 4.2. Retrosynthetic analysis of linear route.
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Studies toward the synthesis of cyclic PNA monomer via 
convergent route
First, alkylation of diaminopurine 4.8 with bromoacetic acid ethyl ester afforded 
alkylated diaminopurine 4.9, and subsequent ester hydrolysis provided diaminopurine 
acetic acid 4.2 (Scheme 4.3).33 Although we attempted direct coupling of diaminopurine 
with bromoacetic acid to obtain diaminopurine acetic acid 4.2, we isolated unidentified 
byproducts along with the product. Therefore, we decided to follow the previous route, 
which provided the clean product.
We decided to use the commercially available disulfide-containing dimer 
cystamine, in which the thiol is inherently protected. First, cystamine dihydrochloride 4.5 
was alkylated with bromoacetic acid benzyl ester to give the dibenzyl ester compound 
4.10 (Scheme 4.4). Deprotection of the benzyl esters to give diacid 4.11 was sluggish 
under hydrogenation conditions. This was possibly due to poisoning of the palladium 
catalyst by sulfur in the substrate. Although deprotection under HCOOH acid and Pd/C 
seemed promising, it required nearly equivalent amounts of Pd/C for an efficient 
reaction.34 Thus, we decided to use a t-butyl ester instead of a benzyl ester for alkylation 
of cystamine 4.5.
Cystamine 4.5 was alkylated with bromoacetic acid f-butyl ester to give the di-t- 
butyl ester compound 4.12 in 46% yield (Scheme 4.5). Then, disulfide bond cleavage of 
dimer 4.1235 using TCEP36 gave monomer 4.13,37 and removal of the f-butyl ester with 
TFA provided mercaptoethyl glycine 4.1438 in quantitative yield. With 4.14 in hand, next 
we investigated the formation of thiomorpholinone 4.3 under peptide coupling and 
dehydration conditions. However, we were not able to successfully isolate the product. 
This was possibly due to the free amine interfering with the reactive thioester bond.
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Scheme 4.5. Synthetic attempts for cyclic PNA monomer 4.3.
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Next, we decided to protect the free amine to avoid the aforementioned 
problems. Deciding on the best protecting group that would require mild deprotection 
conditions became demanding. Solid phase peptide synthesis (SPPS)39,40 using Fmoc40 
protecting groups is known to be more attractive than SPPS using Boc protecting groups 
due to the milder basic deprotection of Fmoc in comparison to the harsh acidic 
conditions required for Boc. However, the use of popular SPPS Fmoc removal base, 
piperidine, becomes problematic when thioester functional groups are present in the 
substrates. Previous work has reported the use of DBU as a safe alternative to 
piperidine in the presence of the thioester functionality.41,42 Hence, we chose Fmoc as 
the choice of protecting group for our substrate 4.12.35
Accordingly, Fmoc protection of the amino groups of 4.1235 provided the di-Fmoc 
protected compound 4.15, and subsequent disulfide bond cleavage gave the cyclization 
precursor 4.1643 (Scheme 4.6). The known thiol compound 4.16 was then subjected to 
dehydration conditions under Dean-Stark apparatus to provide Fmoc-protected 
thiomorpholinone product 4.17.44 However, isolation of thiomorpholinone 4.3 after 
removal of the Fmoc group was not successful under numerous conditions. This could 
possibly be due to the instability of the thioester group and the reactivity of the 
secondary amine group. Consequently, we decided not to isolate the free amine 
compound 4.3, and instead attempt a one-pot procedure for Fmoc removal from 4.17 
and subsequent amide bond formation with diaminopurine acetic acid 4.2 to give the 
desired cyclic PNA monomer 4.1 (Scheme 4.7). Accordingly, we investigated an addition 
of Fmoc protected thiomorpholinone 4.17 to the activated acid of 4.2, with a base in the 
medium. However, we were not able to isolate the product 4.1, nor completely recover 
the starting thiomorpholinone 4.17.
Although our attempts to optimize the conditions of the aforementioned one-pot 
synthesis are currently underway, we propose an alternative route for future attempts by
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Scheme 4.7. Synthetic attempts for cyclic PNA monomer 4.1.
modifying our choice of protecting groups. We anticipate that alkylation of cystamine 4.5 
with bromoacetic acid ethyl ester, followed by protection of the diamines with a Boc 
protecting group will provide 4.18 (Scheme 4.8). Then, we envision that sequential 
disulfide cleavage, ester hydrolysis, and thiolactonization45 will afford 4.19. We predict 
that acidic deprotection of the Boc group will not hydrolyse the thioester, thus enabling 
isolation of thiomorpholinone 4.3 as a TFA salt. Finally, amide bond formation with Boc- 
protected diaminopurine acetic acid 4.20, followed by Boc removal, would provide the 
desired cyclic PNA monomer 4.1 as a TFA salt.
Meanwhile, we also attempted the linear route that we initially proposed. 
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Scheme 4.8. Proposed convergent synthetic route for cyclic PNA monomer 4.1.
ester protected dimer 4.10 seemed promising, t-butyl ester protected dimer 4.12 yielded 
decomposed material (Scheme 4.9), and we did not further investigate this route. 
Nevertheless, in future attempts, we recommend the use of Boc protected diaminopurine 
acetic acid 4.20 for coupling to minimize side reactions.
Conclusion
The research presented here shows our initial efforts towards synthesizing the 
desired PNA monomer 4.1. Some of the difficulties associated with successful isolation 
of the desired PNA monomer can be attributed to the labile thioester moiety being 
sensitive to aqueous, basic, and nucleophilic conditions. This indeed challenges the use 
of this monomer in future experiments, which would be mainly conducted under aqueous 
conditions. However, previous successful examples of the use of thioesterification and 
thioester functional groups in experimental settings similar to physiological conditions 
suggest the viability of our monomer in similar settings.
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Scheme 4.9. Synthetic attempts via proposed linear route.
Upon synthesis of the monomer, the ability of base pairing and base stacking to 
drive the templated polymerization will be investigated. If successful, our efforts will lead 
to a templated PNA polymerization system that can execute polymerization from single­
monomer building blocks with high fidelity.
Glassware for all reactions was oven dried or flame dried and cooled prior to use. 
All reactions were run under an atmosphere of nitrogen or argon unless otherwise 
stated. Dichloromethane (CH2Cl2) and dimethylformamide (DMF) were passed through a 
solvent purification system (J. C. Meyer). Unless otherwise noted, all starting materials 
were obtained from commercial suppliers and were used without further purification. 
Thin layer chromatography was performed on Silica gel 60 F254 plates eluting with the 
solvent indicated, visualized by a 254/365 nm UV lamp, or stained with a solution of 
ninhydrin, p-anisaldehyde, or potassium permanganate. Column chromatography was 
performed on Merck silica gel Kieselgel 60 (230-400 mesh, 40-63 ^m particle size) or 
aluminium oxide (activated, neutral, Brockmann 1, ~150 mesh, 58 A pore size). Yields 
were calculated for material judged homogenous by thin layer chromatography and 
NMR. Compounds were named using CS ChemBioDraw Ultra 12.0. NMR spectra were
Experimental Section
General techniques
acquired on a Varian Unity-300 or VXR 500 spectrometer. Chemical shifts for 1H NMR 
spectra are reported in parts per million relative to the signal of residual CHCl3 at 7.27 
ppm or the center line of the residual DMSO pentet at 2.50 ppm. Chemicals shifts for 13C 
NMR spectra are reported in parts per million relative to the center line of the CDCl3 
triplet at 77.23 ppm or the center line of the DMSO septet at 39.51 ppm. The 
abbreviations s, d, t, m, br, and rot stand for singlet, doublet, triplet, multiplet, broad, and 
rotamer, respectively. IR spectra were obtained from Nicolet 380 FT-IR spectrometer. 
Mass spectra were recorded at the Mass Spectrometry facility in the Department of 





2-(2,6-Diamino-9H-purin-9-yl)acetic acid 4.2. To a suspension of 2,6- 
diaminopurine 4.8 (2.00 g, 13.3 mmol) in dry DMF (25 mL) was added portionwise NaH 
(0.586 g, 60% in oil, 14.7 mmol) under an atmosphere of N2. After stirring for 40 min, 
ethyl bromoacetate (1.92 mL, 17.3 mmol) was added and the reaction mixture was 
stirred at rt for 20 h. The reaction mixture was then filtered over a pad of Celite® and the 
clear orange solution was reduced in volume. The mixture was dissolved in EtOAc and 
washed with sat. NH4Cl. The organic layer was separated and the aqueous layer was 
extracted with EtOAc (3x). The combined organic extracts were washed with brine, dried 
over Na2SO4, and concentrated to afford alkylated diaminopurine 4.9,33 which was used
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forward without further purification.
To the above crude product 4.933 (13.3 mmol) in dioxane:H2O (1:1, 40 mL) was 
added 2.5 M NaOH (30 mL) for 5 min at 0 °C. After stirring for 15 min, ice bath was 
removed, and stirred at rt for 1 h. Then the mixture was washed with EtOAc and the 
aqueous layer was acidified to ~pH 3 with HCl. The solid product was filtered, washed 
with water, and dried over Drierite™ under vacuum to yield diaminopurine acetic acid 4.2 
(0.60 g, 22%) as a pale orange solid (Rf = 0.1 in 9:1 CH2Cl2:MeOH); 1H NMR (500 MHz, 
DMSO) 5 7.66 (s, 1 H), 6.65 (br s, 2 H), 5.79 (br s, 2 H), 4.69 (s, 2 H); IR (neat): 3416, 
1662, 1003, 823, 761 cm-1; HRMS (ESI) m/z for C7H8N6O2: 209.0791 (calcd [M+H]+ 
209.0787).
Dibenzyl-2,2'-((disulfanediylbis(ethane-2,1-diyl))bis(azanediyl))diacetate 
4.10. To a suspension of cystamine dihydrochloride 4.5 (6.00 g, 26.6 mmol) and KI 
(0.221 g, 1.33 mmol) in acetonitrile (100 mL), Et3N (16.3 mL, 117 mmol) was added for 5 
min at rt under an atmosphere of N2. Then benzyl bromoacetate (8.4 mL, 53 mmol) was 
added for 5 min. After stirring for 20 h, the reaction mixture was concentrated, dissolved 
in EtOAc, and washed with sat. NH4Cl. The organic layer was separated and the 
aqueous layer was extracted with EtOAc (3x). The combined organic extracts were 
washed with brine, dried over Na2SO4, and concentrated to a brown oil. The crude 
mixture was purified by alumina (activated, neutral) flash column chromatography (9:1 
CH2Cl2:MeOH) to yield dibenzyl ester 4.10 (2.63 g, 22%) as a yellowish brown oil (Rf = 
0.6 in 9:1 CH2Cl2:MeOH); 1H NMR (500 MHz, CDCl3) 5 7.37 (m, 10 H), 5.18 (s, 4 H), 
3.50 (s, 4 H), 2.96 (t, J = 6.2 Hz, 4 H), 2.83 (t, J = 6.4 Hz, 4 H), 1.98 (br s, 2 H); 13C
O
4.10
NMR (125 MHz, CDCfe) 171.7, 135.4, 128.2, 128, 127.97, 66.1, 50.2, 47.5, 38.7; IR 
(neat): 3032, 2914, 1733, 1455, 1140, 978, 737 cm-1; LRMS (ESI) m/z for C22H28N2O4S2: 
449.1 (calcd [M+H]+ 449.16), 471.1 (calcd [M+Na]+ 471.14).
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Di-fert-butyl-2,2'-((disulfanediylbis(ethane-2,1-diyl))bis(azanediyl))diacetate 
4.12. To a suspension of cystamine dihydrochloride 4.5 (5.00 g, 22.2 mmol) and KI 
(0.737 g, 4.44 mmol) in acetonitrile (150 mL), Et3N (13.0 mL, 93.2 mmol) was added for
10 min at rt under an atmosphere of N2. After stirring for 5 min, f-butyl bromoacetate (6.9 
mL, 47 mmol) was added for 10 min. After stirring for 40 h, the reaction mixture was 
refluxed for 3 h, cooled to rt, and TBAI (0.01 eq.) was added. The mixture was refluxed 
for another 3 h and stirred at rt for 20 h. Then the reaction mixture was filtered to remove 
a white precipitate and filtrate was concentrated. The concentrate was dissolved in 
EtOAc, washed with sat. NH4Cl and brine, dried over Na2SO4, and concentrated to a 
brown oil. The crude mixture was purified by alumina (neutral, activated) flash column 
chromatography (a gradient of 8:2 EtOAC:Hexane to 9:1 CH2Cl2:MeOH) to yield di-f- 
butyl ester 4.12 (3.88 g, 46%) as a yellowish brown oil (Rf = 0.8 in 9:1 CH2Cl2:MeOH); 1H 
NMR (500 MHz, CDCl3) 5 3.2 (s, 4 H), 2.81 (t, J = 6.1 Hz, 4 H), 2.70 (t, J = 6.3 Hz, 4 H), 
2.12 (br s, 2 H), 1.34 (s, 18 H); 13C NMR (75 MHz, CDCl3) 171.2, 81.1, 51.3, 47.7, 38.8,
28.0 IR (neat): 2977, 1731, 1456, 1367, 1228, 1154 cm-1; HRMS (ESI) m/z for 





(9H-fluoren-9-yl)methyl2-oxothiomorpholine-4-carboxylate 4.17. To a soluti­
on of di-f-butyl ester 4.12 (2.10 g, 5.53 mmol) in CH2Cl2 (55 mL), FmocOSu (3.768 g,
11.17 mmol) was added at 0 oC under an atmosphere of N2. After stirring for 5 min, Et3N 
(1.6 mL, 11.2 mmol) was added for 5 min and stirred at 0 oC for 0.5 h. Then the reaction 
mixture was warmed to rt and stirred for 16 h. The mixture was concentrated and 
purified by silica flash column chromatography (a gradient of EtOAC:Hexane from 2:8 to 
8:2) to yield the di-Fmoc compound 4.15 (1.01 g, 22%) as a yellowish oil (Rf = 0.3 in 1:1 
EtOAC:Hexane), which was subjected to next step without further characterization.
To the above product 4.15 (0.423 g, 0.513 mmol) in MeOH (10 mL), TCEP (0.147 
g, 0.513 mmol) was added at 0 oC under an atmosphere of N2. After stirring for 5 min, 
ice bath was removed and stirred at rt for 25 min. The mixture was concentrated, 
triturated with Et2O, and concentrated. Then the resulting white precipitate was dissolved 
in Et2O. Et2O layer was separated and concentrated to yield the known thiol 4.16 (crude 
0.32 g, 77%),43 as a yellow oil, which was subjected to next step without further 
purification.
To the above crude thiol 4.1643 (0.44 mmol) in toluene (5 mL), TsOH H2O 
(0.083 g, 0.44 mmol) was added (prior to the addition, TsOHH2O was dissolved in 
benzene and concentrated). The mixture was refluxed under Dean-Stark apparatus for 
16 h (the reaction set up was covered with Al foil during the reaction). The reaction 
mixture was purified by silica flash column chromatography (1:1 EtOAC:Hexane) to 
afford thiomorpholinone 4.17 (0.071 g, 48%) as a pale yellow oil (Rf = 0.6 in 1:1 
EtOAC:Hexane); 1H NMR (500 MHz, CDCh) 7.75 (d, J = 6.7 Hz, 2 H), 7.53 (s, 2 H), 7.39
(t, J = 7.4 Hz, 2 H), 7.31 (t, J = 7.4 Hz, 2 H), 4.56-4.48 (m, 2 H), 4.27-4.2 (m, 3 H), 3.82 
(br s, 1 H, rot 1), 3.61 (br s, 1 H, rot 2), 3.21 (br s, 1 H, rot 1), 2.98 (br s, 1 H, rot 2); 13C 
NMRmajor rotamer (125 MHz, CDCfe) 195.6, 154.8, 143.7, 141.5, 128.1, 127.3, 125, 120.3, 
68.2, 55.5, 47.4, 42.7, 28.7; IR (neat): 2921, 1699, 1451, 1227, 1117, 739 cm-1; HRMS 
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CHAPTER 5
A MULTIVALENT SCAFFOLD FOR USE IN THE SYNTHESIS OF 
DNA-POLYMER CONJUGATES 
Introduction
The molecular recognition properties of biomacromolecules can be tailored to 
develop programmable materials for biosensing and controlled drug release. In 
particular, targeted drug delivery and release in a stimuli-responsive manner has 
significant potential for use in therapeutics, but substantial challenges remain, including 
low efficacy, occurrence of side effects, and uncontrolled release.1,2 Numerous drug 
delivery systems, including micelles, have been investigated to overcome the 
aforementioned challenges.3 Micelles are formed by the self-assembly of amphiphilic 
monomers into well-defined, three-dimensional nanostructures having a hydrophobic 
core and a hydrophilic surface in aqueous environments. Thus, small, hydrophobic 
molecules can be entrapped in the core region of the micelles.
Due to the dynamic nature of micelles, guest molecules are in equilibrium with 
the surrounding solution and can diffuse out. In addition, micelles can be dissociated by 
high temperatures, low monomer concentrations, and changes in surrounding solvent 
conditions, thus leading to an uncontrolled release of entrapped molecules.4 
Consequently, numerous methods have been explored to covalently crosslink the 
micellar monomers, such as radical polymerization and disulfide bond formation,4 and 
the stability and rate of guest molecule release from crosslinked micelles are directly 
proportional to crosslink density.5
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Micellar structures that can dissociate in a stimuli-responsive manner using pH, 
light, temperature, and redox potential have been reported.6 Additionally, amphiphilic 
micelles containing DNA7 as the hydrophilic component have been used in various 
applications such as nucleic acid detection8 and drug delivery.9,10 For example, 
anticancer micelles have been designed for targeting folate receptors, which are highly 
expressed in many types of cancers, including ovarian, lung, breast, and bladder.11 DNA 
strands of these micellar monomers were conjugated to folic acid, which can recognize 
the folate receptors of cancer cells.10 In addition, doxorubicin was incorporated in the 
hydrophobic core of micelles. The selective uptake of these doxorubicin-loaded micelles 
resulted in the death of cancer cells, without affecting the normal cells. However, the 
assembly, disassembly, and guest release of micelles, triggered by the response of DNA 
to a specific chemical or biological signal, has yet to be explored.
The Heemstra group has proposed the design of programmable DNA-based 
micelles to control the release of guest molecules using the molecular recognition 
properties of DNA. In contrast to covalent crosslinking,4 we hypothesized that the 
inherent Watson-Crick base pairing12 between complementary DNA strands could 
provide noncovalent crosslinks that can stabilize the micellar structure, preventing the 
escape of guest molecules. In addition, these DNA-crosslinked micelles (DCMs) will be 
designed to respond to stimuli such as nucleic acids, small molecules, or enzymes that 
can disrupt the DNA crosslinks. Consequently, specific chemical or biological signals will 
be converted into the physical outputs of micelle dissociation and guest release (Figure 
5.1).
We envisioned that DCMs would perform a multitude of applications, ranging 
from biosensors to drug carriers, depending on the nature of the guest molecules and 
DNA sequences. For instance, DCMs would act as a user-friendly biosensor, giving a 
visual output when the guest molecule is a solvatochromic dye that is sensitive to
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Figure 5.1. Stimuli-responsive dissociation of DNA-crosslinked micelles (Stimuli: small 
molecule, nucleic acid, or restriction endonuclease).
solvent polarity. If the DCMs are prepared by incorporating a therapeutic agent, they 
would act as a selective drug delivery vehicle capable of releasing the payload upon 
exposure to a specific toxin or pathogen. Quick, stimuli-responsive drug release is 
essential in many situations, such as war zones or areas hit with an epidemic crisis. For 
instance, the survival rate of army personnel and civilians exposed to chemical or 
biological warfare agents can be enhanced by pretreatment with micelles containing 
drugs known to counteract these harmful agents. Thus, the chemical or biological stimuli 
from warfare agents will disrupt the micelle, facilitating immediate drug release.
Aptamers are nucleic acid sequences that selectively bind to small molecules or 
proteins and can be generated for a wide range of targets using the SELEX process.13-15 
We envision that functionalizing the micellar monomers with known aptamers will 
facilitate the disassembly of the micelles upon exposure to the desired target (small 
molecule or nucleic acid), releasing the guest molecules. Similarly, when DCMs have 
complementary sequences of the EcoRI target sequence, crosslinks can be cleaved in 
the presence of restriction endonuclease enzymes.
To develop our DCMs, we intended to synthesize amphiphilic monomers 
comprised of DNA strands (including known aptamers) and hydrophobic polymers 
(including PNIPAAm) joined through a central multivalent scaffold. The DNA strands
within each monomer would be identical to one another in sequence and orientation. We 
would also synthesize a second monomer having DNA sequences complementary to the 
first. In addition, in order to have the desired crosslinking throughout the micelle, each 
monomer should have at least three (ideally four) DNA strands. A monomer having only 
two DNA strands (A2) can only form an isolated dimer with a complementary monomer 
(B2), preventing further crosslinks (Figure 5.2). However, when four DNA strands are 
present on one monomer, though two DNA strands of monomer (A4) pair with two DNA 
strands of a complementary monomer (B4), and steric effects would avoid further 
dimerization. Sequential base pairing between complementary DNA sequences on 
different monomers would then form noncovalent crosslinks to facilitate the assembly of 
the micellar structure and the entrapment of small guest molecules.
Our desired central scaffold would contain azide and alkyne moieties installed in 
the same synthetic unit, enabling it to undergo azide-alkyne cycloaddition with nucleic 
acids and polymers in a modular fashion to generate multivalent amphiphilic monomers 
(Figure 5.3).16 This modular assembly would facilitate the optimization of multivalent 
scaffold by enabling variation in the extent of crosslinking, and hydrophobicity of the 
polymer. Originally, we decided to use calix[4]arene as the central unit of multivalent 
scaffold, as it is an attractive macrocyclic receptor in supramolecular chemistry, having a 
rigid, bowl-shaped structure that can be easily functionalized.17 It can hold four spatially 
segregated DNA strands, and also, calixarene-DNA conjugates are known to form 
micellar structures.18 Outlined here in this chapter are studies directed toward the design 
and synthesis of a potential micellar scaffold.
Results and Discussion
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Our original design was to synthesize calixarene-based multivalent scaffold 5.1
(Scheme 5.1). The upper rim of calixarene 5.2 was converted to azidomethyl calixarene
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Figure 5.2. Monomers having two or four DNA strands (a) monomers having two DNA 
strands may form isolated dimers, (b) monomers having four DNA strands dimerize but 








Figure 5.3. Modular assembly of multivalent micellar monomer.
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Scheme 5.1. Synthetic attempts for calixarene-based multivalent scaffold 5.1.
5.3 in a two-step procedure.19 Then, we investigated phenolic alkylation with TIPS- 
protected propargyl bromide 5.4a in the lower rim of calixarene.20 As it was not 
successful, alkylation with less sterically hindered TMS-protected propargyl bromide 
5.4b was attempted. After several synthetic attempts using numerous methods, 
however, we could not optimize suitable reaction conditions for installing the alkynes in 
the presence of the azides, or vice versa.
Therefore, we redesigned the multivalent scaffold; the desired multivalent 
scaffold is required to have at least three azide functionalities for the attachment of DNA 
and preferably two or more protected alkyne functionalities for the attachment of polymer 
chains. Our second generation designs were 5.5 with two alkynes and three azides, and
5.6 with two alkynes and four azides (Figure 5.4). In this chapter, we will only discuss the 
synthesis of 5.5, as we were not able to complete the synthesis of 5.6 during the time 
frame of the project.
Retrosynthesis of multivalent scaffold 5.5
We envisioned that the desired multivalent scaffold 5.5 would arise from a 
convergent route via the phenolic etherification between gallic acid amide compound 5.7 
and azido iodopropane 5.8 (Scheme 5.2). The amide bond formation between gallic acid
















Scheme 5.2. Retrosynthetic analysis of multivalent scaffold 5.5.
Synthesis of multivalent scaffold 5.5
In order to synthesize the TIPS-protected subunit 5.10, commercially available 2- 
aminoglycerol 5.11 was reacted with Boc2O to give Boc-protected amine 5.12 (Scheme 
5.3).21 Although the direct coupling of 5.12 with TIPS-protected propargyl bromide20 and 
KOH was attempted, basic reaction conditions led to the removal of the TIPS group, 
yielding dipropargylic ether compound 5.13 in 40% yield. Instead, treatment of amine 
5.12 with propargyl bromide and KOH afforded the dipropargylic ether compound 5.13.
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Scheme 5.3. Synthesis of amine coupling precursor 5.10.
Subsequent deprotonation of the alkyne of 5.13 and treatment with TIPSCl provided the 
TIPS-protected dipropargylic ether compound 5.14. Finally, removal of the Boc- 
protecting group of 5.14 with TFA afforded the TIPS-protected bis-alkyne portion of 
scaffold 5.10.
Next, we investigated coupling of amine 5.10 with the central subunit in the 
scaffold, gallic acid 5.9. Previous work has reported amide bond formation with gallic 
acid while having the phenolic groups unprotected.22 Therefore, different amide bond 
formation conditions were screened with unprotected gallic acid 5.9 and amine precursor
5.10 to obtain gallic acid amide 5.7 (Scheme 5.4). However, we were not successful in 
isolating the desired product under these conditions due to polymerization, as indicated 
by mass values from MALDI-MS. Next, coupling conditions a, b, and c were investigated 
with gallic acid trimethyl ether 5.15 to obtain amide 5.16. We found that both b and c 
conditions gave the desired amide product (Scheme 5.5). However, the attempt to 
remove methyl ethers of 5.16 with BBr3 was unsuccessful.
Consequently, we decided to investigate amide coupling condition with acetyl-
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Scheme 5.6. Synthesis of gallic acid amide 5.7.
protected gallic acid 5.17. Next, coupling of 5.17 with amine 5.10 using HATU/DIPEA 
conditions yielded gallic acid amide compound 5.18. In addition, acetyl-protected amine 
5.19 was isolated as a byproduct. Different ester hydrolysis conditions were then 
investigated to remove acetyl esters of 5.18, and finally, basic hydrolysis with NaHCO3 
yielded the phenol coupling precursor 5.7.24 Concurrently, 1-azido-3-iodopropane 5.8 
was synthesized as previously reported.25,26 Lastly, etherification of phenols of 5.7 by 




Scheme 5.7. Synthesis of multivalent scaffold 5.5.
Conclusion
DNA-based micelles have potential to serve as stimuli-responsive materials due 
to their ability to undergo programmable assembly and disassembly. In order to develop 
our desired DCMs, we anticipated synthesizing amphiphilic monomers containing DNA 
strands and hydrophobic polymers joined through a central, multivalent scaffold. We 
were not able to successfully synthesize the calixarene-based scaffold 5.1 during the 
time frame of the project, but we were able to synthesize second generation multivalent 
scaffold 5.5 via a convergent route. However, attempts to find conditions to couple three 
DNA strands to obtain the amphiphilic monomer were not successful, likely due to 
unfavorable steric effects.27 Studies to generate DNA-based micelles using new 
scaffolds are currently underway.
Experimental Section 
General techniques
Glassware for all reactions was oven dried or flame dried and cooled prior to use.
All reactions were run under an atmosphere of nitrogen or argon unless otherwise
111
stated. Tetrahydrofuran (THF) was distilled from sodium and benzophenone. 
Dichloromethane (CH2Cl2) and dimethylformamide (DMF) were passed through a 
solvent purification system (J. C. Meyer). Unless otherwise noted, all starting materials 
were obtained from commercial suppliers and were used without further purification. 
Thin layer chromatography was performed on Silica gel 60 F254 plates eluting with the 
solvent indicated, visualized by a 254/365 nm UV lamp, or stained with a solution of 
ninhydrin, p-anisaldehyde, or potassium permanganate. Column chromatography was 
performed on Merck silica gel Kieselgel 60 (230-400 mesh, 40-63 ^m particle size). 
Yields were calculated for material judged homogenous by thin layer chromatography 
and NMR. Compounds were named using CS ChemBioDraw Ultra 12.0. NMR spectra 
were acquired on a Varian Unity-300, Inova 400, or VXR 500 spectrometer. Chemical 
shifts for 1H NMR spectra are reported in parts per million relative to the signal of 
residual CHCl3 at 7.27 ppm. Chemicals shifts for 13C NMR spectra are reported in parts 
per million relative to the center line of the CDCl3 triplet at 77.23 ppm. The abbreviations 
s, d, dd, t, p, m, and br stand for singlet, doublet, doublet of doublets, triplet, pentet, 
multiplet, and broad, respectively. IR spectra were obtained from Nicolet 380 FT-IR 
spectrometer. Mass spectra were recorded at the Mass Spectrometry facility in the 
Department of Chemistry of the University of Utah.
Procedures and characterizations 
TI PS— — \
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(tert-Butyl(3,3,15,15-tetraisopropyl-2,16-dimethyl-7,11-dioxa-3,15-disilahept 
adeca-4,13-diyn-9-yl)carbamate 5.14. To a solution of Boc-protected 2-aminoglycerol
5.1221 (2.000 g, 10.46 mmol) in DMF (40 mL), propargyl bromide (80 wt.% in toluene, 
2.80 mL, 31.4 mmol) were added at 0 °C under a nitrogen atmosphere. Then portions of 
finely ground KOH (2.349 g, 41.86 mmol) were added over a period of 15 min. The 
reaction mixture was then heated to 35 °C and stirred for 24 h. To the resulting brown 
mixture, ethyl acetate (10 mL) was added, poured into a separatory funnel containing 
ethyl acetate, and washed with water (3x30 mL). The organic layer was washed with 
brine, dried over Na2SO4, and concentrated. The crude material was purified by silica 
flash column chromatography (a gradient of EtOAC:Hexane from 1:9 to 3:7) to yield 
propargyl coupled amine 5.13 (1.73 g, 62%) as a brown oil (Rf = 0.8 in 3:7 
EtOAC:Hexane). The amine was subjected to the alkyne TIPS protection without further 
characterization.
To the above product 5.13 (1.73 g, 6.48 mmol) in THF (70 mL), LDA (1.8 M in 
THF, 12.6 mL, 22.7 mmol) was added at -78 °C under a nitrogen atmosphere. After 
stirring for 30 min, TIPSCl (3.16 mL, 14.9 mmol) was added and stirred at -78 oC for 10 
min. Then the reaction mixture was warmed to rt and stirred for 2 h. The reaction mixture 
was concentrated and dissolved in CH2Cl2. The resulting mixture was washed with 2 N 
HCl and brine, dried over Na2SO4, and concentrated. The crude material was purified by 
silica flash column chromatography (a gradient of EtOAC:Hexane from 5:95 to 3:7) to 
afford TIPS-protected alkyne 5.14 (3.0 g, 80%) as a pale yellow oil (Rf = 0.8 in 3:7 
EtOAC:Hexane); 1H NMR (500 MHz, CDCl3) 5 4.93 (d, J = 7.7 Hz, 1 H), 4.37-4.27 (m, 1 
H), 4.19 (dd, J = 16.2, 4.7 Hz, 4 H), 3.63-3.62 (m, 4 H), 1.44 (s, 9 H), 1.07 (s, 42 H); 13C 
NMR (125 MHz, CDCl3) 155.5, 103.3, 87.8, 79.3, 68.3, 59.2, 49.5, 28.4, 18.7, 11.3; IR 
(neat): 2943, 2865, 1721, 1500, 1464, 1366, 1252, 1100, 998, 883 cm-1; HRMS (ESI) m/z 




The TFA salt of 3,3,15,15-tetraisopropyl-2,16-dimethyl-7,11-dioxa-3,15- 
disilaheptadeca-4,13-diyn-9-amine 5.10. To a solution of the alkyne-TIPS-protected 
amine product 5.14 (2.42 g, 4.18 mmol) in CH2Cl2 (40 mL), TFA (5 mL) was added 
dropwise at 0 °C under an atmosphere of N2. After the addition, reaction mixture was 
stirred at 0 °C for 15 min. Then the reaction mixture was slowly warmed to rt, stirred for 
another 2 h, and concentrated. The trituration of the crude reaction mixture with Et2O 
yielded 5.10, which was used forward without further purification.
OMe
3,4,5-Trimethoxy-N-(3,3,15,15-tetraisopropyl-2,16-dimethyl-7,11-dioxa-3,15- 
disilaheptadeca-4,13-diyn-9-yl)benzamide 5.16. To a solution of gallic acid trimethyl 
ether 5.15 (0.623 g, 2.94 mmol), HATU (1.21 g, 3.18 mmol), and 4 A MS in DMF (12 
mL), DIPEA (3.84 mL, 22.0 mmol) was added at 0 °C under a nitrogen atmosphere. 
After stirring at 0 °C for 10 min, a solution of amine 5.10 (1.173 g, 2.447 mmol) in CH2Cl2 
(15 mL) was added and stirred at 0 °C for 10 min. After stirring at rt for 16 h, the 
reaction mixture was concentrated and dissolved in EtOAc. The resulting mixture was 
washed with H2O, sat. NH4Cl, sat. NaHCO3, and brine. The organic layer was dried over 
Na2SO4, and concentrated. The crude mixture was purified by silica flash column
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chromatography (3:7 EtOAC:Hexane) to yield gallic acid amide 5.16 (0.59 g, 35%) as a 
yellow oil (Rf = 0.5 in 3:7 EtOAC:Hexane); 1H NMR (300 MHz, CDCl3) 5 7.01 (s, 2 H), 
6.58 (d, J = 8.4 Hz, 1 H), 4.54-4.51 (m, 1 H), 4.24 (dd, J = 16.1, 5.4 Hz, 4 H), 3.89 (s, 9 
H), 3.77 (d, J = 5 Hz, 4 H), 1.06 (s, 42 H); 13C NMR (75 MHz, CDCh) 166.7, 153.1, 141,
130, 104.6, 103, 87.9, 68.1, 60.8, 59.1, 56.3, 48.7, 18.5, 11.1; IR (neat): 2941, 2865, 
2171, 1584, 1463, 1352, 1232, 1127, 997, 882, 678 cm-1; HRMS (ESI) m/z for 
C37H63NO6Si2: 696.4104 (calcd [M+Na]+ 696.4092).
N3
3,4,5-Tris(3-azidopropoxy)-N-(3,3,15,15-tetraisopropyl-2,16-dimethyl-7,11- 
dioxa-3,15-disilaheptadeca-4,13-diyn-9-yl)benzamide 5.5. To a solution of tri-acetyl 
protected gallic acid 5.1723 (0.84 g, 2.8 mmol), HATU (1.168 g, 3.073 mmol), and 4 A 
MS in DMF (5 mL), DIPEA (3.7 mL, 21 mmol) was added at 0 °C under a nitrogen 
atmosphere. After stirring at 0 °C for 10 min, a solution of amine 5.10 (1.133 g, 2.364 
mmol) in CH2Cl2 (14 mL) was added and stirred at 0 °C for 10 min. After stirring at rt for 
16 h, the reaction mixture was concentrated and dissolved in EtOAc. The resulting 
mixture was washed with H2O, sat. NH4Cl, and brine. The organic layer was dried over 
Na2SO4 and concentrated. The crude mixture was purified by silica flash column 
chromatography (3:7 EtOAC:Hexane) to yield tri-acetyl gallic amide 5.18 (0.33 g, 18%) 
as a yellow oil (Rf = 0.4 in 3:7 EtOAC:Hexane). The amide was subjected to the next
step without further characterization.
To the above tri-acetyl protected gallic amide 5.18 (0.187 g, 0.247 mmol) in 
MeOH:H2O (5:1, 12 mL), sat. NaHCO3 (8 mL) was added for 20 min at 0 °C. After stirring 
for 1 h, ice bath was removed, and stirred at rt for 7 h. As some starting material was still 
remaining, the reaction mixture was cooled to 0 °C and sat. NaHCO3 (5 mL) added for 
10 min. After stirring for 10 min, ice bath was removed, and stirred at rt. Then, the 
reaction mixture was concentrated and dissolved in EtOAc and H2O. The aqueous layer 
was washed with EtOAc and acidified to ~pH 3 with HCl. The aqueous layer was 
extracted with EtOAc. The organic layer was washed with brine, dried over Na2SO4, and 
concentrated to afford gallic amide 5.7 (crude 0.12 g, 77%), which was used forward 
without further purification.
To the above gallic amide 5.7 (0.1 g, 0.16 mmol) in DMF (0.5 mL), K2CO3 
(0.098 g, 0.71 mmol) was slowly added at 0 °C under a nitrogen atmosphere. After 
stirring at 0 °C for 10 min, a solution of 1-azido-3-iodopropane 5.825,26 (1.12 g, 0.583 
mmol) in DMF (1 mL) was added and stirred at 0 °C for 1 h (Caution! azide containing 
reaction). After stirring at rt for 16 h, the reaction mixture was warmed to ~50 oC and 
stirred for another 16 h. The reaction mixture was filtered, diluted with EtOAc, and 
washed with ~0.5 N HCl. The aqueous layer was extracted with EtOAc. Then, combined 
organic layers were washed with brine, dried over Na2SO4, and concentrated to an oil. 
The crude mixture was purified by silica flash column chromatography (3:7 
EtOAC:Hexane) to afford the multivalent scaffold 5.5 (0.038 g, 27%) as a pale yellow oil 
(Rf = 0.3 in 2:8 EtOAC:Hexane); 1H NMR (500 MHz, CDCl3) 5 7.00 (s, 2 H), 6.40 (d, J =
8.7 Hz, 1 H), 4.52-4.50 (m, 1 H), 4.24 (dd, J = 16.1, 9.4 Hz, 4 H), 4.13 (t, J = 6.5 Hz, 4 
H), 4.07 (t, J = 5.8 Hz, 2 H), 3.75 (d, J = 4.7 Hz, 4 H), 3.60 (t, J = 6.6 Hz, 2 H), 3.55 (t, J 
= 7.6 Hz, 4 H), 2.10 (p, J = 7.4 Hz, 4 H), 2.00 (p, J = 7.4 Hz, 2 H), 1.06 (s, 42 H); 13C 
NMR (100 MHz, CDCl3) 166.7, 152.7, 140.7, 130.5, 106.4, 103.1, 88.3, 70.2, 68.3, 66.2,
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59.4, 53.6, 48.4, 29.9, 29.1, 18.8, 11.3; IR (neat): 2943, 2866, 2096, 1582, 1464, 1354, 
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CHAPTER 6
CONCLUSION AND FUTURE DIRECTIONS
Peptide nucleic acid (PNA)1 shows tremendous potential to be used in numerous 
therapeutic, biosensing, and nanotechnology applications due to its excellent biostability, 
strong binding affinity, and high selectivity toward nucleic acids.2-4 However, PNA faces 
challenges for in vivo applications such as poor solubility, cellular uptake, and 
bioavailability, predominantly due to its uncharged backbone. The Heemstra group 
hypothesized that negatively charged PNA analogues would overcome the 
abovementioned limitations by taking advantage of the delivery methods available for 
DNA and RNA. However, it has been hypothesized that the high binding affinity of PNA 
to DNA and RNA is due to the lack of electrostatic repulsion in duplex formation between 
charge neutral PNA and negatively charged nucleic acids.4 According to this hypothesis, 
incorporation of negative charge to PNA backbone would be detrimental in duplex 
formation with DNA and RNA, yet, there were not any studies in literature that 
investigated this hypothesis. Thus, the major objectives of this dissertation were to 
investigate whether there is a role of electrostatics in PNA:DNA and PNA:RNA duplex 
formation and whether negatively charged groups could be incorporated into the PNA 
backbone without affecting its binding affinity and selectivity with DNA and RNA.
Towards these goals, we explored the effect of ionic strength on binding affinity 
for y-modified PNAs having either negatively charged aspartic acid side chains or 
positively charged lysine side chains.5 We observed that electrostatic effects do play a 
role in binding of PNA to DNA and RNA, as negatively charged PNA shows lowest
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duplex stability at low ionic strength. However, with the increase of ionic strength, charge 
screening of electrostatic repulsion by counterions in solution enables negatively 
charged side chains to be incorporated into the PNA backbone without reducing duplex 
stability with DNA and RNA. Presumably, preorganization of the PNA backbone via 
hydrogen bonding is primarily responsible for the enhanced duplex stability of PNA with 
DNA and RNA.6,7 We observed that at medium to high salt concentrations, negatively 
charged PNA actually binds more strongly to DNA and RNA than does positively charged 
PNA. Interestingly, in a simulated physiological buffer, negatively charged PNA shows 
higher affinity for RNA whereas positively charged PNA shows higher affinity for DNA.
Intrigued by the effect of side chain structure and electrostatics on binding 
affinity, we were also curious to explore the mismatch and orientation selectivity of these 
y-substituted PNAs.8 We found that introduction of y-substituents results in similar or 
slightly decreased selectivity compared to unmodified PNA. However, for y-substituted 
PNAs, positively charged side chains provide higher selectivity in DNA binding and 
negatively charged side chains provide higher selectivity in RNA binding. Although we 
obtained CD spectra to understand these differential binding properties, these studies 
revealed that the side chains do not significantly alter the overall structure of the 
PNA:DNA or PNA:RNA duplexes. However, we hypothesize that side chains may still 
provide sufficient local perturbation to account for the observed differences in affinity and 
selectivity.
Appella and coworkers have previously reported a y-Lys PNA:DNA duplex model 
in which side chains with S stereochemistry orient along the periphery of the duplex, 
whereas side chains with R stereochemistry point towards the interior of the duplex 
(Figure 6.1).9 Similarly, the Ly group observed that methyl group of L-Ala y-PNA point 
towards the solvent (Figure 6.2).10 Thus, y-substituents are less likely to introduce steric 
effects on base pairing and base stacking interactions of a duplex.11 In addition, the
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Figure 6.1. y-Lys PNA:DNA duplex model [Side chain derived from l-(S)-lysine projects 
away from the duplex (blue) and side chain from d-(R)-lysine projects into the minor 
groove (yellow). Purple=base pairs, orange=PNA backbone, and fuscia=DNA 
backbone]. Reproduced with permission from (Englund, E. A.; Appella, D. H. Angew. 
Chem., Int. Ed. 2007, 46, 1414-1418), copyright © (2007) WILEY-VCH Verlag GmbH & 
Co. KGaA, Weinheim.
Figure 6.2. Solution structure of L-Ala y-PNA determined from NMR (arrow points 
toward the backbone carbonyl group and y-methyl group in the circled region). Adapted 
with permission from (Dragulescu-Andrasi, A.; Rapireddy, S.; Frezza, B. M.; Gayathri, 
C.; Gil, R. R.; Ly, D. H. J. Am. Chem. Soc. 2006, 128, 10258-10267). Copyright © (2006) 
American Chemical Society.
carbonyl oxygen of the PNA backbone points towards the solvent (in trans configuration 
with y-Me group) and the backbone-nucleobase linker amide points towards the carboxyl 
end of backbone.12 Furthermore, 1D and 2D NMR studies of y-PNA suggest that y-Me 
groups are orientated away from the duplex, but in the edge between minor and major 
groove.11
We envision that y-substituents could non-covalently interact with the backbone 
carbonyl group, as pointed out by the arrow in Figure 6.2. Among intra-residue non- 
covalent interactions, y-Lys PNA could exhibit favorable hydrogen bonding and 
electrostatic attractions whereas y-Asp PNA could induce electrostatic repulsion effects 
(Figure 6.3). In y-Lys PNA, favorable electrostatic effects could bring the side chain in 
close proximity to the backbone but in y-Asp PNA, unfavorable interactions could point 
the side chain away from the backbone. We hypothesize that Lys PNA:DNA duplex can 
accommodate the side chain of Lys in the wide major groove but with RNA, these 
electrostatic interactions could give rise to unfavorable steric effects due to its narrow 
major groove. Unfavorable electrostatic effects could interfere with the duplex formation 
of Asp-PNA with DNA and RNA. However, with RNA these electrostatic effects can be 
screened more efficiently by counterions than in the case of DNA, as A-form helices are 
known to recruit a higher density of counter ions than B-form helices.13 Although our 
hypothesis provides a possible explanation for the differential binding properties that we 
observed, exact conclusions cannot be derived from the limited structural data that is 
currently available for y-PNA. Thus, in the future, extensive structural information is 
required to thoroughly understand our results.
Typical A-form and B-form helices have 11 and 10.5 base pairs per turn, 
respectively. Most of the previous structural studies utilized 10-mer sequences of PNA,10 
presumably due to the sequence length which gives one helical turn. Further studies are 
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Figure 6.3. Potential noncovalent interactions between PNA backbone and y-side chain 
(for clarity: all the potential interactions are not shown).
that the differential binding properties are independent of PNA sequence length. It 
should be noted that the aspartic acid and lysine monomers used in this initial study 
have slightly different side chain lengths. Future investigations are needed to explore the 
effect of side chain length on duplex stability and mismatch discrimination, to confirm 
that the differential binding properties predominantly arise due to altered charges of side 
chains rather than the side chain lengths. In addition, further work is necessary to 
understand the effect of numerous side chains and sequences, and the effect of 
positioning of the side chains relative to the mismatch site on binding affinity and 
selectivity.
PNA can bind to DNA and RNA in both parallel and antiparallel orientations 
because of its achiral backbone, but generally prefers the antiparallel orientation. 
Introduction of y-substituents had previously been shown to favor unambiguous 
antiparallel binding.10 However, we observed that unmodified PNA discriminates parallel 
versus antiparallel orientations better than modified PNA. y-substituted PNAs have a 
rigid right handed helical structure with less conformational freedom than unmodified 
PNA. Therefore, in duplex formation, DNA and RNA may undergo conformational 
changes to accommodate y-PNA, rather than y-PNA undergoing changes to bind to DNA 
and RNA.14 Thus, we assume that under the salt conditions that we studied, DNA and 
RNA binding to right handed y-PNA in the parallel orientation is entropically favorable.
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Whereas, unmodified PNA has more conformational flexibility and needs to preorganize 
into a right handed-helix in binding to DNA and RNA, which imposes a higher entropic 
penalty in duplex formation in the parallel orientation. Further work must be carried out 
under different salt conditions to validate the observed orientation selectivity of y-PNA.
In general, we perceived that the error associated with PNA:RNA duplex data is 
higher than with DNA. This could be due to the greater instability of RNA than DNA in 
long cycles of thermal melting (Tm) experiments. However, it is interesting to see whether 
the error can be minimized by using a new sample of PNA:RNA duplex in each trial of Tm 
studies. In addition, the simulated physiological buffer used for this initial study mimics 
the extracellular salt conditions. Therefore, it is desirable to investigate the binding 
properties in a buffer mimicking intracellular salt conditions. Also, the salt dependent 
melting properties should be examined with varying concentrations of other monovalent 
cations including lithium and potassium, instead of sodium.
Our results provide insight into the impact of PNA side chain structure and 
electrostatics on the binding affinity and selectivity with DNA and RNA in antisense and 
antigene applications. Since PNA can be negatively charged without sacrificing binding 
affinity and selectivity, we anticipate that these molecules will show promise as 
therapeutics that take advantage of both the inherent benefits of PNA and the multitude 
of charge-based delivery technologies currently being developed for DNA and RNA. 
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APPENDIX A
SPECTRAL DATA OF CHAPTER 2: 1H AND 13C NMR, HPLC, MALDI-TOF, UV-
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Reinjected HPLC traces and MALDI-TOF data fo r PNA oligomers.
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b)
m/z 2727.48 (calcd [M]+ 2727.04).





m/z 2785.54 (calcd [M]+ 2785.04).
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b)
m/z 2902.67 (calcd [M+H]+ 2902.14); 2924.68 (calcd [M+Na]+ 2924.12).





m/z 2800.76 (calcd [M+H]+ 2799.12); 2822.71 (calcd [M+Na]+ 2821.1).




m/z 2941.38 (calcd [M+H]+ 2941.26); 2963.37 (calcd [M+Na]+ 2963.24).





m/z 2740.99 (calcd [M]+ 2741.05); m/z 2741.96 (calcd [M+H]+ 2942.06); 2763.93 (calcd
[M+Na]+ 2764.04).





m/z 2769.99 (calcd [M+H]+ 2770.08); 2792.03 (calcd [M+Na]+ 2792.06).
Figure A.7. HPLC and MALDI-TOF MS of PNA 3Me (H-GTaAGATaCACTa-NH2).
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Figure A.8. Representative UV-melting curves of DNA 1:DNA 2 duplex under varying 
salt concentrations.
Table A.1. Tm data (oC) for DNA 1:DNA 2 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 n.d. 28.6 33.1 37.7 40.7 42.7
Trial 2 n.d. 28.6 33.1 37.7 40.7 42.2
Trial 3 n.d. 28.6 33.1 37.7 40.7 42.7
Average n.d. 28.6 ± 0.1 33.1 ± 0.1 37.7 ± 0.1 40.7 ± 0.1 42.6 ± 0.3
(n.d.- not determined)
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Figure A.9. Representative UV-melting curves of PNA nf:DNA 1 duplex under varying 
salt concentrations.
Table A.2. Tm data (oC) for PNA nf:DNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 47.3 45.2 44.2 43.7 43.2 43.7
Trial 2 46.8 44.2 43.7 43.2 42.2 42.7
Trial 3 44.8 43.7 43.2 43.2 41.7 42.2
Average 46.3 ± 1.3 44.4 ± 0.8 43.7 ± 0.5 43.4 ± 0.3 42.4 ± 0.8 42.9 ± 0.8
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Figure A.10. Representative UV-melting curves of PNA 1neg:DNA 1 duplex under vary­
ing salt concentrations.
Table A.3. Tm data (oC) for PNA 1neg:DNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 46.3 45.8 46.3 46.8 46.8 46.8
Trial 2 45.8 44.8 44.8 45.2 45.2 45.8
Trial 3 45.2 44.2 43.7 43.7 44.2 45.2
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Figure A.11. Representative UV-melting curves of PNA 3neg:DNA 1 duplex under vary­
ing salt concentrations.
Table A.4. Tm data (oC) for PNA 3neg:DNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 43.6 48.5 46.7 48.5 49.1 49.7
Trial 2 43.6 47.3 46.7 47.9 47.3 48.5
Trial 3 43.4 46.7 46.1 47.9 47.9 48.5
Average 43.6 ± 0.1 47.5 ± 0.9 46.5 ± 0.4 48.1 ± 0.3 48.1 ± 0.9 48.9 ± 0.7
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Figure A.12. Representative UV-melting curves of PNA 1pos:DNA 1 duplex under vary­
ing salt concentrations.
Table A.5. Tm data (oC) for PNA 1pos:DNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 57.6 50.3 49.7 49.7 48.5 47.9
Trial 2 55.8 49.1 47.9 48.5 47.3 47.3
Trial 3 54.6 48.5 47.9 47.9 47.3 47.3




Figure A.13. Representative UV-melting curves of PNA 3pos:DNA 1 duplex under vary­
ing salt concentrations.
Table A.6. Tm data (oC) for PNA 3pos:DNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 62.7 58.1 54.1 49.6 48.9 47.6
Trial 2 61.4 58.1 51.5 46.3 46.3 45.6
Trial 3 60.7 57.4 51.5 46.9 46.9 45.0
Trial 4 52.2 48.2 46.3 46.9
Average 61.6 ± 1.0 57.9 ± 0.4 52.3 ± 1.2 47.7 ± 1.5 47.1 ± 1.2 46.3 ± 1.2
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Figure A.14. Representative UV-melting curves of PNA 1Me:DNA 1 duplex under vary­
ing salt concentrations.
Table A.7. Tm data (oC) for PNA 1Me:DNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 52.8 51.3 50.3 49.8 49.3 49.3
Trial 2 52.3 50.3 49.8 49.3 48.8 48.8
Trial 3 51.3 49.8 49.3 48.8 48.3 48.8
Average 52.2 ± 0.8 50.5 ± 0.8 49.8 ± 0.5 49.3 ± 0.5 48.8 ± 0.5 49.0 ± 0.3
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Figure A.15. Representative UV-melting curves of PNA 3Me:DNA 1 duplex under vary­
ing salt concentrations.
Table A.8. Tm data (oC) for PNA 3Me:DNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 43.2 41.7 42.2 41.2 39.7 39.2
Trial 2 42.7 42.7 43.2 42.7 40.2 40.7
Trial 3 43.7 42.7 42.7 41.7 41.7 42.2
Average 43.2 ± 0.5 42.4 ± 0.6 42.7 ± 0.5 41.9 ± 0.8 40.5 ± 1.1 40.7 ± 1.5
149
Figure A.16. Representative UV-melting curves of RNA 1:DNA 2 duplex under varying 
salt concentrations.
Table A.9. Tm data (oC) data for RNA 1 :DNA 2 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 n.d. 27.6 31.1 35.2 37.7 39.2
Trial 2 n.d. 27.1 31.6 35.7 37.7 39.2
Trial 3 n.d. 28.1 32.1 35.7 38.2 38.7
Average n.d. 27.6 ± 0.5 31.6 ± 0.5 35.5 ± 0.3 37.8 ± 0.3 39.0 ± 0.3
(n.d.- not determined)
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Figure A.17. Representative UV-melting curves of PNA nf:RNA 1 duplex under varying 
salt concentrations.
Table A.10. Tm data (oC) for PNA nf:RNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 47.8 47.3 48.3 48.3 48.8 49.3
Trial 2 47.8 46.3 47.3 46.8 47. 8 48.3
Trial 3 46.8 45.8 46.3 46.3 46.8 47.8
Average 47.4 ± 0.6 46.4 ± 0.8 47.3 ± 1.0 47.1 ± 1.1 47.8 ± 1.0 48.5 ± 0.8
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Figure A.18. Representative UV-melting curves of PNA 1neg:RNA 1 duplex under vary­
ing salt concentrations.
Table A.11. Tm data (oC) for PNA 1neg:RNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 48.8 48.3 48.8 49.8 50.3 54.8
Trial 2 48.3 46.8 47.3 48.3 49.3 53.3
Trial 3 47.8 45.8 46.3 47.3 47.8 52.3
Average 48.3 ± 0.5 46.9 ± 1.3 47.4 ± 1.3 48.5 ± 1.3 49.1 ± 1.3 53.5 ± 1.3
152
20 30 40 50 60 70 80
Temperature (°C)
Figure A.19. Representative UV-melting curves of PNA 3neg:RNA 1 duplex under vary­
ing salt concentrations.
Table A.12. Tm data (oC) for PNA 3neg:RNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 49.7 52.1 50.9 53.3 55.2 55.8
Trial 2 49.7 53.3 51.5 53.3 53.9 56.4
Trial 3 50.9 52.1 51.5 53.9 53.3 55.2
Average 50.1 ± 0.7 52.5 ± 0.7 51.3 ± 0.4 53.5 ± 0.4 54.1 ± 0.9 55.8 ± 0.6
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Figure A.20. Representative UV-melting curves of PNA 1pos:RNA 1 duplex under vary­
ing salt concentrations.
Table A.13. Tm data (oC) for PNA 1pos:RNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 55.8 48.5 50.3 51.5 52.7 53.3
Trial 2 55.2 46.1 47.9 49.1 50.9 52.1
Trial 3 53.3 46.1 48.5 49.1 50.9 52.1
Trial 4 46.7 48.5 49.7 50.9
Average 54.7 ± 1.3 46.9 ± 1.4 48.3 ± 1.5 49.5 ± 1.3 51.1 ± 1.2 52.1 ± 1.0
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Figure A.21. Representative UV-melting curves of PNA 3pos:RNA 1 duplex under vary­
ing salt concentrations.
Table A.14. Tm data (oC) for PNA 3pos:RNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 58.1 54.7 51.8 49.5 51.5 52.5
Trial 2 56.8 54.1 50.4 47.6 49.6 49.7
Trial 3 56.8 54.8 52.5 46.9 50.9 50.4
Average 57.2 ± 0.8 54.6 ± 0.4 51.6 ± 1.1 48.0 ± 1.3 50.6 ± 1.0 50.9 ± 1.5
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Figure A.22. Representative UV-melting curves of PNA 1Me:RNA 1 duplex under vary­
ing salt concentrations.
Table A.15. Tm data (oC) for PNA 1Me:RNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 51.8 51.3 51.3 52.3 53.8 54.3
Trial 2 50.3 49.8 51.2 52.3 53.8 54.8
Trial 3 49.3 49.3 49.3 50.3 52.3 52.8
Average 50.5 ± 1.3 50.1 ± 1.1 50.6 ± 1.1 51.6 ± 1.1 53.3 ± 0.9 54.0 ± 1.0
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Figure A.23 Representative UV-melting curves of PNA 3Me:RNA 1 duplex under vary­
ing salt concentrations.
Table A.16. Tm data (oC) for PNA 3Me:RNA 1 duplex under varying salt concentrations.
[NaCl] = 0 M 50 mM 100 mM 250 mM 500 mM 1 M
Trial 1 38.7 40.7 41.2 42.2 42.2 44.2
Trial 2 39.2 40.7 41.2 42.7 42.2 43.7
Trial 3 40.2 41.2 41.2 42.7 43.2 43.7
Average 39.4 ± 0.8 40.9 ± 0.3 41.2 ± 0.1 42.6 ± 0.3 42.6 ± 0.6 43.9 ± 0.3
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Representative UV-melting curves and Tm data for duplexes under physiological 
salt conditions.
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Figure A.24. Representative UV-melting curves of PNA/DNA 2:DNA 1 duplexes under 
physiological salt conditions.
Table A.17. Tm data (oC) for PNA/DNA 2:DNA 1 duplexes under physiological salt condi­
tions.
complement = DNA 2 PNA nf PNA 1neg PNA 1pos PNA 3neg PNA 3pos
Trial 1 37.2 43.7 46.8 47.3 46.7 50.2
Trial 2 37.2 42.7 45.8 46.7 46.1 48.9
Trial 3 37.2 43.2 45.2 46.8 45.4 48.2
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Figure A.25. Representative UV-melting curves of PNA/DNA 2:RNA 1 duplexes under 
physiological salt conditions.
Table A.18. Tm data (oC) for PNA/DNA 2:RNA 1 duplexes under physiological salt condi­
tions.
complement = DNA 2 PNA nf PNA 1neg PNA 1pos PNA 3neg PNA 3pos
Trial 1 33.1 48.3 49.3 47.8 51.5 48.2
Trial 2 32.6 46.8 47.8 46.7 49.7 46.3
Trial 3 31.6 46.3 47.3 46.3 48.5 45.0
Average 32.5 ± 0.8 47.1 ± 1.1 48.1 ± 1.1 46.9 ± 0.8 49.9 ± 1.5 46.5 ± 1.7
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Figure A.26. Representative UV-melting curves of PNA 1Me and PNA 3Me duplexes 
under physiological salt conditions.
Table A.19. Tm data (oC) for PNA 1Me and PNA 3Me duplexes under physiological salt 
conditions.








Trial 1 48.8 39.7 49.7 41.7
Trial 2 46.8 39.7 47.9 41.7
Trial 3 46.3 40.7 46.7 40.7
Average 47.3 ± 1.3 40.0 ± 0.6 48.1 ± 1.5 41.4 ± 0.6
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Representative UV-melting curves and Tm data fo r duplexes
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Figure B.1. Representative UV-melting curves of PNA nf:DNA duplexes 
under simulated physiological salt conditions.
Table B.1. Tm data (oC) for PNA nf:DNA duplexes under simulated physiological salt 
conditions.









Trial 1 43.6 32.5 36.4 31.8 33.8
Trial 2 43.0 32.5 35.8 33.1 30.5
Trial 3 42.3 32.5 36.4 32.5 31.2
Trial 4 31.2
Average 43.0 ± 0.7 32.5 ± 0.1 36.2 ± 0.3 32.5 ± 0.7 31.7 ± 1.5
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Figure B.2. Representative UV-melting curves of PNA 3neg:DNA 
duplexes under simulated physiological salt conditions.
Table B.2. Tm data (oC) for PNA 3neg:DNA duplexes under simulated physiological salt 
conditions.









Trial 1 46.9 41.0 41.7 44.3 43.6
Trial 2 46.3 40.4 41.0 41.0 43.6
Trial 3 45.6 40.4 39.7 42.3 42.3
Trial 4 43.0







Figure B.3. Representative UV-melting curves of PNA 3pos:DNA 
duplexes under simulated physiological salt conditions.
Table B.3. Tm data (oC) for PNA 3pos:DNA duplexes under simulated physiological salt 
conditions.









Trial 1 50.2 40.4 38.4 39.7 41.7
Trial 2 48.9 37.7 37.7 38.4 39.0
Trial 3 48.2 38.4 37.7 39.0 40.4
Trial 4 37.7 39.0
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Figure B.4. Representative UV-melting curves of PNA nf:RNA duplexes 
under simulated physiological salt conditions.
1
0
Table B.4. Tm data (oC) for PNA nf:RNA duplexes under simulated physiological salt 
conditions.









Trial 1 48.3 37.1 27.9 28.5 30.5
Trial 2 46.8 36.4 28.5 27.9 30.5
Trial 3 46.3 36.4 29.2 29.2 32.5
Average 47.1 ± 1.111 36.6 ± 0.4 28.5 ± 0.7 28.5 ± 0.7 31.2 ± 1.2
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Figure B.5. Representative UV-melting curves of PNA 3neg:RNA 
duplexes under simulated physiological salt conditions.
Table B.5. Tm data (oC) for PNA 3neg:RNA duplexes under simulated physiological salt 
conditions.









Trial 1 51.5 41.7 30.5 34.4 39.0
Trial 2 49.7 40.4 31.2 34.4 40.4
Trial 3 48.5 39.0 29.2 33.1 37.7
Trial 4 39.0 39.0
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Figure B.6. Representative UV-melting curves of PNA 3pos:RNA 
duplexes under simulated physiological salt conditions.
0
Table B.6. Tm data (oC) for PNA 3pos:RNA duplexes under simulated physiological salt 
conditions.









Trial 1 48.2 42.3 39.0 38.4 40.4
Trial 2 46.3 40.4 37.7 36.4 39.0
Trial 3 45.0 39.7 38.4 36.4 39.7
Average 46.5 ± 1.711 40.8 ± 1.3 38.4 ± 0.7 37.1 ± 1.2 39.7 ± 0.7
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Figure B.7. Representative UV-melting curves of mismatched PNA:DNA 3 
duplexes under simulated physiological salt conditions.
Table B.7. Tm data (oC) for mismatched PNA:DNA 3 duplexes under 











Trial 1 32.5 44.9 39.7
Trial 2 33.8 44.3 37.7
Trial 3 31.8 43.6 37.0
Average 32.7 ± 1.0 44.3 ± 0.7 38.1 ± 1.4
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Figure B.8. Representative UV-melting curves of mismatched PNA:RNA 3 
duplexes under simulated physiological salt conditions.
Table B.8. Tm data (oC) for mismatched PNA:RNA 3 duplexes under 











Trial 1 31.2 38.4 36.4
Trial 2 29.8 37.7 35.8
Trial 3 29.2 37.7 35.7
Average 30.1 ± 1.0 37.9 ± 0.4 36.0 ± 0.4
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SPECTRAL DATA OF CHAPTER 5: 1H AND 13C NMR DATA
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